bioRxiv preprint doi: https://doi.org/10.1101/2021.10.01.462632; this version posted October 1, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

1	Direct Reprogramming of Non-limb Fibroblasts to
2	Cells with Properties of Limb Progenitors
3	
4	Yuji Atsuta <sup>1, 4, 8, *</sup> , Changhee Lee <sup>1, 8</sup> , Alan R. Rodrigues <sup>1, 5, 8</sup> , Charlotte Colle <sup>1, 6</sup> ,
5	Reiko R. Tomizawa <sup>1</sup> , Ernesto G. Lujan <sup>1, 2</sup> , Patrick Tschopp <sup>1, 7</sup> , Joshua M. Gorham <sup>1</sup> ,
6	Jean-Pierre Vannier <sup>3</sup> , Christine E. Seidman <sup>1</sup> , Jonathan G. Seidman <sup>1</sup> , Olivier
7	Pourquié <sup>1, 2, *</sup> and Clifford J. Tabin <sup>1, 9, *</sup>
8	
9	1: Department of Genetics, Harvard Medical School, 77 Avenue Louis Pasteur, Boston,
10	MA 02115, USA
11	2: Department of Pathology, Brigham and Women's Hospital, 60 Fenwood Road,
12	Boston, MA 02115, USA
13	3: Unité Inserm U1234/Université de Rouen/IRIB, 76183 Rouen Cedex, France
14	4: Present address: Department of Biology, Faculty of Sciences, Kyushu University,
15	Fukuoka 819-0395, Japan
16	5: Present address: The Rockefeller University, 1230 York Avenue, New York, NY
17	10065
18	6: Present address: Department of Cell and Developmental Biology, University
19	College London, London WC1E 6BT, UK
20	7: Present address: Zoological Institute, University of Basel, 4051 Basel, Switzerland
21	8: These authors contributed equally
22	9: Lead contact
23	*Correspondence: <u>atsuta.yuji.360@m.kyushu-u.ac.jp</u> (Y.A.),
24	pourquie@genetics.med.harvard.edu (O.P.),
25	tabin@genetics.med.harvard.edu (C.J.T.)

1

## 2 SUMMARY

The early limb bud consists of mesenchymal progenitors (limb progenitors) derived 3 4 from the lateral plate mesoderm (LPM) that produce most of the tissues of the mature limb bud. The LPM also gives rise to the mesodermal components of the trunk, flank 5 and neck. However, the mesenchymal cells generated at these other axial levels 6 7 cannot produce the variety of cell types found in the limb bud, nor can they be directed to form a patterned appendage-like structure, even when placed in the context of the 8 9 signals responsible for organizing the limb bud. Here, by taking advantage of a direct reprogramming approach, we find a set of factors (Prdm16, Zbtb16, and Lin28) 10 normally expressed in the early limb bud, that are capable of imparting limb progenitor-11 like properties to non-limb fibroblasts. Cells reprogrammed by these factors show 12 similar gene expression profiles, and can differentiate into similar cell types, as 13 endogenous limb progenitors. The further addition of Lin41 potentiates proliferation of 14 the reprogrammed cells while suppressing differentiation. These results suggest that 15 these same four key factors may play pivotal roles in the specification of endogenous 16 limb progenitors. 17

1

## 2 INTRODUCTION

Limb bud progenitors originate from the somatopleural layer of the LPM, a continuous 3 4 epithelium lining the embryonic coelom. Limb progenitors emerge through localized epithelial-to-mesenchymal transition (EMT) at limb forming levels (Gros and Tabin, 5 2014). Limb progenitors will ultimately give rise to the majority of tissues present in 6 7 the mature patterned limb including cartilage, bone, tendon, ligament, muscle connective tissue and dermis; whereas somatopleural LPM at other axial levels, such 8 9 as neck and flank mesenchyme, will only form dermis. Moreover, limb progenitors are organized within the limb bud in response to limb-patterning morphogenic signals. 10 while LPM-derived cells from other axial levels are refractory to them (Takeuchi et al., 11 2003). It has, however, remained unclear what gene, or genes, are responsible for 12 specifying limb progenitors and imparting them with limb-specific traits. 13

In previous studies, direct cellular reprogramming has been used to induce a 14 variety of tissue progenitor populations, such as neural progenitors, cardiomyocytes 15 and hepatocytes, from terminally differentiated fibroblasts (Vierbuchen et al., 2010). 16 These studies not only set the stage for future therapeutic applications, but they have 17 also proven important, in and of themselves, for identifying developmental regulators 18 19 of embryonic progenitor states (Takahashi and Yamanaka, 2015). For example, the 20 reprogramming factors first shown to be capable of inducing pluripotent stem cells (Oct3/4, Sox2, Klf4 and c-Myc) were subsequently shown to regulate the endogenous 21 developmental signaling network defining mouse embryonic stem cells (Lin et al., 22 23 2008).

To understand what it really means to be a limb progenitor, we set out to identify a set of factors expressed ubiquitously in the early limb field, that might be capable of

establishing and maintaining the unique transcriptional characteristics and
differentiation potential of limb progenitors. To that end, we took a reprogramming
approach, reasoning that a full set of the factors giving early limb progenitors their
unique properties might be sufficient to convert non-limb mouse embryonic fibroblasts
into cells with properties of limb progenitors.

We started with 18 candidate factors expressed in early limb progenitors. We 6 7 overexpressed these factors via viral vectors in three-dimensional (3D) culture conditions optimized for maintaining legitimate limb progenitors. This pool of 18 factors 8 9 was, indeed, able to robustly induce expression of limb progenitor marker genes in mouse embryonic non-limb fibroblasts. Winnowing the candidates responsible for this 10 activity, we ultimately found that, a combination of two transcription factors, Prdm16 11 and Zbtb16, plus an RNA-binding protein, Lin28a, suffice to reprogram non-limb 12 fibroblasts into a limb progenitor-like state (reprogrammed limb progenitor-like cells, 13 hereafter rLPCs). Moreover, the further addition of Lin41 (also known as Trim71), 14 boosts proliferation of rLPCs, by antagonizing translation of Eqr1, a pro-differentiation 15 factor for limb progenitors. The limb progenitor-like state of the rLPCs was validated 16 at a transcriptional level, and through in vitro and in vivo differentiation assays. While 17 our initial analysis was carried out with murine cells, we further show that adult human 18 fibroblasts can similarly be converted to rLPCs with the same set of factors used for 19 20 mouse cell reprogramming, suggestive of conservation of the genetic program for limb bud initiation across vertebrates. Taken together, the reprogramming factors identified 21 here are capable of conferring non-limb cells with limb progenitor specific traits, 22 23 suggesting that these factors might similarly initiate developmental networks that define the endogenous early limb progenitors as they emerge from the LPM. 24

25

1

## 2 **Results**

## **3** Optimization of culture conditions for early mouse limb bud progenitors

Prior to embarking on a reprogramming strategy, we needed to establish culture 4 conditions capable of sustaining authentic limb progenitors, to assure that putative 5 reprogrammed limb progenitor-like cells would be able to expand into colonies while 6 7 maintaining a limb progenitor-like identity. 3D-culture systems mimicking physiological conditions have been used to support expansion of primary progenitor populations 8 9 such as neural and nephron progenitor cells (Madl et al., 2017; Li et al., 2016), as well as for cellular reprogramming of iPSCs (Caiazzo, 2016). To mimic the early limb bud 10 extracellular environment, we exploited hydrogel scaffolds made from high molecular 11 weight hyaluronic acid (HA) and adipic acid dihydrazide crosslinkers. HA is a large 12 glycosaminoglycan that is known to be a major component of the extracellular matrix 13 (ECM) of the developing limb buds (Li et al., 2007). 14

In a previous study, we showed that treating cultured chick limb bud cells with 15 a combination of Wnt3a, Fgf8 and retinoic acid (RA) maintained them in a progenitor 16 state for 48 hours (Cooper et al., 2011). Here, we utilized CHIR99021, a GSK3 inhibitor 17 in place of Wnt3a. We compared the effect of these factors on mouse limb progenitors, 18 19 cultured within a 3D-HA-gel scaffold with those maintained in two-dimensional culture 20 on polystyrene plastic. To provide a readout for maintenance of a limb progenitor identity, we harvested limb bud progenitors from E9.5 Prx1-GFP reporter mice (Prx1-21 CreER-ires-GFP)(Kawanami et al., 2009), in which GFP activity is specifically seen in 22 23 the limb buds (Fig. 1A). While the GFP signal was maintained in 2-D culture conditions for the first 48 hours, there was no stimulation of cell proliferation (Fig S1A), and the 24 GFP activity was rapidly lost at later time points. In contrast, under 3-D HA-gel 25

conditions, the plated cells expanded over 20-fold during this time (Fig. 1A, B). With 1 subsequent culture, however, the cell number diminished. Moreover, the expression 2 of three different early limb bud markers, Prx1-GFP, Lhx2 and Sall4, were only 3 maintained for the first 2 days of culture (Fig. 1C and S1B) (Rodriguez-Esteban et al., 4 1998). Reasoning that the loss of limb progenitors could be due to differentiation, cell 5 death, or both, we added Y-27632, a Rho-associated kinase inhibitor (as this factor is 6 7 known to suppress dissociation-associated cell death of stem/progenitor cells) (Watanabe et al., 2007); and SB431542, a TGFβ/BMP antagonist (as TGFβ and BMP) 8 9 act as pro-differentiation factors for tendons and cartilage, respectively) (Healy et al., 1999). Media supplemented with this combination of CHIR, Fgf8, RA, SB431542 and 10 Y-27632 greatly increased proliferation of limb progenitors (Fig. 1B). Moreover, 49.2% 11 of the cultured cells in the HA-gels remained PrxGFP<sup>+</sup>/Lhx2<sup>+</sup>/Sall4<sup>+</sup>-positive for at least 12 8 days (Fig. 1A, C and S1B). To see if this set of factors could maintain the 13 differentiation potential of cultured limb progenitors, GFP-expressing chicken limb 14 progenitors were kept in a 3D-HA gel supplemented by these factors for 8 days, and 15 were then grafted into host limb buds (Chapman et al., 2005). When observed 5 days 16 later, the transplanted GFP-chick cells were integrated into both cartilage expressing 17 Sox9<sup>+</sup> (Fig. S2A), and muscle associated tendon, expressing Collagen I (Fig. S2B) 18 indicating that limb progenitors cultured in the 3D-HA-gel in the presence of the 19 20 defined set of factors maintained their potency to differentiate into limb tissue types.

Finally, we asked whether other culture matrices besides HA could maintain limb progenitors in the presence of CHIR99021, Fgf8, RA, SB431542 and Y-27632. Several scaffolds we tested failed to do so, however we discovered that limb bud cells plated onto Matrigel grew to a similar extent, and maintained expression of limbspecific markers, equivalent to those seeded into the HA scaffold (Fig. S3A-C).

Accordingly, the HA and Matrigel systems were used interchangeably in subsequent
 experiments as noted below (being careful to always compare to controls cultured in
 the same matrix).

4

## 5 Identification of candidate genes for specification of limb progenitor identity

To generate a list of candidate transcription factors potentially involved in early limb 6 7 fate specification, we used RNA-seq to identify genes expressed exclusively in the early chick limb fields. We harvested the forelimb and hindlimb buds of HH17-19 8 9 embryos, as well as presumptive neck and flank mesenchyme from HH19-20 embryos (Fig. 1D). Additionally, we profiled the epithelial lateral plate mesoderm prior to forelimb 10 bud emergence (HH15; Fig. 1D). The transcriptional profiles of these tissues were 11 compared in a principal component analysis (PCA). The first and second PC 12 accounted for 48% and 28% of the variance in the five data sets. When plotted in the 13 principal component space, the forelimb and hindlimb bud tissues clustered together 14 tightly (Fig. S4A). PC1 separates the remaining three tissues from the limb tissues 15 while PC2 separates epithelial lateral plate and neck mesenchyme from the limb 16 tissues (Fig. S4A). To determine the key drivers of this separation in PC space, the 17 top 100 genes contributing to each principal component were used in a gene set 18 enrichment analysis. For both PC1 and PC2, the top five most significant classes of 19 20 gene function were related to transcriptional regulation (Fig. S4B), suggesting that the drivers of difference between limb and non-limb lateral plate mesenchyme are 21 transcription factors. We then intersected our existing mouse hindlimb bud 22 23 transcriptional data set (Tschopp et al., 2014) with our chick data to generate an evolutionarily conserved set of candidate genes we could use in a reprogramming 24 assay. Of the 1806 transcriptional regulators in the mouse genome, 303 are expressed 25

at appreciable levels in the mouse hindlimb. Of these 303 genes, 142 are co-1 expressed in both the chick forelimb and hindlimb. Of this core set of 142 transcription 2 factors, co-factors and chromatin remodelers, we particularly were interested in those 3 that were differentially expressed relative to the neck and/or flank mesenchyme. Only 4 15 of the 142 factors were more than two-fold over-expressed in the limb as compared 5 to the neck and 16 were more than two-fold overexpressed when compared to the 6 7 flank (Fig. 1E). Among those genes, we excluded Lhx9 and Hoxa6 as these genes were deemed potentially redundant to Lhx2 and other Hox genes, respectively. Sall4 8 9 was replaced with Sall1, a multi-zinc finger transcription factor that functions redundantly with Sall4 (Bohm et al., 2008), because a reliable antibody against Sall4 10 was available, which could be considered as a proxy for the reprogramming. Lmx1b 11 was withdrawn because it specifies only the dorsal compartment of the limb field (Chen 12 et al., 1998), and Snai1/2 was removed from the list because limb-specific double 13 mutants show no defect in limb bud formation (Chen and Gridley, 2013). In addition, 14 we included several genes such as Tbx5 and Pbx2, which were not differentially 15 expressed relative to the flank tissue, but were expressed in both the chicken and 16 mouse limb progenitors, and had been previously implicated functionally as being 17 important for limb bud outgrowth (Takeuchi et al., 2003; Capellini et al., 2006). 18

Finally, we added Lin28a to the list. Lin28a is a highly conserved RNA-binding protein, the major function of which is to bind nascent *let-7* micro RNA in order to block its biogenesis (Viswanathan et al., 2008). Lin28a plays roles in regulating development and pluripotency (Tsialikas and Romer-Seibert, 2015), and is known as one of the iPSC reprogramming factors (Yu et al., 2007). Of note, expression of *Lin28a* mRNA has been specifically seen in early limb buds, in both mouse and chicken embryos, and its expression is downregulated as limb development progresses (Buganim et al.,

2014). Moreover, we observe a relatively higher expression level of Lin28a in mouse
limb buds than in the flank lateral plate mesoderm (Fig. 1F). Taken together, this
generated a list of 18 candidate reprogramming factors.

4

## Overexpression of candidate genes specifically expressed in early limb buds activates expression of limb progenitor genes in non-limb fibroblasts

7 We isolated GFP-negative fibroblasts from the non-limb regions of E13.5 *Prx1*-GFP transgenic embryos. These non-limb fibroblasts were infected with pooled 8 9 retroviruses transducing our 18 candidate factors, and were cultured under the conditions optimized for legitimate limb progenitors (Fig. 1G). Taking advantage of the 10 limb-specific GFP activity as an indicator of reprogramming, we asked if the pooled 18 11 candidate factors could induce GFP expression in non-limb fibroblasts. Indeed, 14 12 days after infection, the emergence of GFP positive cells became apparent. Of interest, 13 a fraction of the GFP positive cells formed clusters reminiscent of freshly harvested 14 limb progenitors cultured in the same conditions (Fig. 1A, H). While the Prx1 promoter 15 strongly drives expression in limb buds, it is also expressed in some other regions of 16 the embryo, such as the head mesoderm. Thus, we examined expression of other limb 17 progenitor marker genes as well (Fig. 1I, J). We observed induction of increased Sall4 18 protein levels by immunohistochemistry (Fig. 11), as well as increased transcript levels 19 20 of other limb progenitor markers (Prx1-GFP, Fgf10, FgfR2c, Msx2, Hoxd9, Lhx9, Meis2, Dusp6 and Axin2) measured by gPCR (Fig. 1J). Strikingly, each of these 21 markers was upregulated in infected cells relative to non-limb fibroblasts (Fig. 1J). 22 23 These results suggest that the pool of the candidate factors can convert non-limb bud fibroblasts to a state with at least some similarities to limb progenitors. 24

25

### 1 Combinatorial overexpression of Prdm16, Zbtb16 and Lin28a induces limb

### 2 progenitor marker expression in non-limb fibroblasts

Next, to identify which of the factors in our initial pool were responsible for the induction 3 of limb progenitor marker genes, we examined the effect of withdrawing individual 4 factors from the mix on the activation of the Prx1 promoter, as reflected by GFP 5 expression (18-1 factor assay; Fig. S5). Efficiency of the induction was measured as 6 7 a GFP score, which was calculated by dividing the GFP positive area by total area staining with DAPI (Fig. 2A). We found that removal of any of 7 factors (Hoxd10, 8 9 Zbtb16, Lhx2, Prdm16, Etv4, Tfap2a and Lin28a) resulted in a decrease in the GFP score, implying that these 7 factors were significant contributors to GFP induction (Fig. 10 2A). The combination of these 7 genes alone produced GFP positive cells efficiently, 11 whereas withdrawal individual factors from the 7 factors pool decreased GFP scores 12 (7-1 factor assay; Fig. S6A). We further conducted a 7-2 factor assay, in which 13 combination of two factors were excluded from the 7 factors pool (Fig. S6B). We found 14 that in both the 7-1 and 7-2 assays, Lin28a was necessary to yield a high GFP score 15 (Fig. S6A and S6B). Moreover, Lin28 is required for induction of a second limb 16 progenitor marker, Sall4 (Fig. S6A). Consistent with these results, Lin28 alone was 17 sufficient to generate PrxGFP and Sall4 positive cell aggregates from non-limb 18 fibroblasts (Fig. S6C), although other limb makers such as Lhx2 were not induced. To 19 20 attain more complete reprogramming, we built on the Lin28a finding as a core factor, utilizing a Lin28a plus one factor assay (Fig. 2B, C). Although overexpression of Lin28a 21 could not trigger Lhx2 expression (Fig. S6C), combination of Lin28a and either Zbtb16 22 23 or Prdm16 induced Lhx2 in addition to GFP and Sall4 (Fig. 2B, C). Combinatorial overexpression of both Prdm16 and Zbtb16 with Lin28a yielded even higher GFP 24 scores (17.9 in Fig. 2B). Furthermore, transcript levels of representative limb 25

1 progenitor genes were upregulated in the GFP-positive reprogrammed cells (Fig. 2D).

2 Therefore, we defined these three as our core set of factors for limb reprogramming.

The reprogramming factors we identified are expressed in both endogenous forelimb and hindlimb buds. To ask whether the reprogrammed cells acquired forelimb or hindlimb-like identity, we examined the expression levels of *Tbx5* and *Tbx4*, genes responsible for specification of the forelimb and hindlimb, respectively (Rodriguez-Esteban et al., 1999). We found that *Tbx5*, but not *Tbx4*, is induced in the reprogrammed cells, suggesting that the non-limb fibroblasts obtained forelimb-like traits through the overexpression of the reprogramming factors (Fig. 2E).

As noted above, we found that the clusters of reprogrammed cells were 10 morphologically reminiscent of endogenous limb progenitors. To more rigorously 11 assess this impression, we used forward scatter profiling to measure cell size, via flow 12 cytometry. As expected from direct observation, the values of the reprogrammed cells 13 were smaller than those of non-limb fibroblasts, and in the similar range to authentic 14 limb progenitors (Fig. S7A). We also quantified and compared the size of nuclei 15 (DAPI<sup>+</sup>) in unreprogrammed fibroblasts with that in the reprogrammed cells, and found 16 the area of DAPI<sup>+</sup> was decreased after reprogramming (Fig. S7B), again similar to the 17 measured DAPI area of limb progenitors. Together, the reprogrammed cells share 18 transcriptional and morphological similarities with legitimate early limb progenitors, 19 20 and henceforth are termed as reprogrammed limb progenitor-like cells, or rLPCs.

21

## Overexpression of Egr1 suppresses limb progenitor proliferation and induces precocious differentiation of chicken limb progenitors

The results described above suggest that Pdrm16, Zbtb16 and Lin28a can in concert, convert non-limb fibroblasts into rLPCs. Lin28a in particular was the most

indispensable in our 7-1 and 7-2 assays. Accordingly, we further investigated the role 1 of Lin28a in rLPC reprogramming, in order to gain a more mechanistic understanding 2 of the processes. Potential insight into this question came from consideration of its 3 function as an iPSC reprogramming factor. In that context, Lin28a acts to block 4 production of the Let-7 microRNA. This is significant because the let-7 target, Lin41 5 suppresses translation of *Eqr1*, which in turn antagonizes upregulation of pluripotency 6 7 genes. Thus, in the presence of Lin28a, Lin41 activity promotes iPSC reprogramming (Ecsedi and Grosshans, 2013). Of note, *let-7a* is present in the chick limb buds and 8 9 its expression level is increased as limb outgrowth proceeds (Lancman et al., 2005), corresponding to downregulation of Lin28a expression (Yokoyama et al., 2008). Lin41 10 mRNA is also expressed in the early chicken and mouse limb mesenchyme (Lancman 11 et al., 2005; fig. S8A). Conversely, Egr1 is not expressed in E9.5 or 10.5 mouse limb 12 progenitors, nor is it seen in the forelimb-forming region of HH15 chicken embryos (Fig. 13 3A, S8A). However, Egr1 is detectable in differentiating limb progenitors and tenocytes 14 of E13.5 mouse forelimb buds (Fig. 3B and S8B). These observations are consistent 15 with Lin28a inhibiting *let-7a* in early limb buds, thereby preventing degradation of *Lin41*, 16 and hence maintaining a limb progenitor state. Egr1 is also expressed in the non-limb 17 fibroblasts used for reprogramming (Fig. 3B), suggesting that Egr1 may act to promote 18 differentiation in the absence of reprogramming, as previously described in the human 19 20 dermal fibroblasts used for iPSC reprogramming (Worringer et al., 2013).

To test if Egr1 indeed plays a role in the regulation of limb progenitors during limb development, human EGR1 coding sequences were electroporated into the somatopleural layer at the prospective forelimb level of HH13 chicken embryos, prior to the expression of endogenous *Egr1* mRNA (Fig. 3C-F). Limb mesenchyme electroporated with a control vector bicistronically expressing H2B-mCherry and

1 ZsGreen was widely distributed in the limbs of HH21 embryos, whereas EGR1transfected cells were located only around the coelomic epithelium, suggesting that 2 overexpression of EGR1 either blocked these cells from entering the limb bud, or 3 interfered with their distal migration (Fig. 3C, D). The EGR1-electroporated limbs were 4 significantly reduced in length potentially attributable to the prohibition of limb 5 progenitor migration, and also reflecting an attenuated level of cell proliferation, which 6 7 was revealed by immunostaining for the mitotic marker phospho-Histone H3 (pH3), (Fig. 3D, E). Moreover, we found that the differentiation markers Sox9 and Col1 were 8 9 induced in the EGR1-electroporated cells, meaning that these cells were precociously differentiated into chondrocytes or tenocytes (Fig. 3F). These data suggest that the 10 EGR1 activity in limb progenitors drives cells towards differentiation, and hence its 11 overexpression can disturb proper limb development, which may deteriorate the 12 efficacy of rLPC reprogramming. 13

14

### 15 Addition of Lin41 accelerates proliferation of rLPCs

Given that Eqr1 appears to oppose the rLPC reprogramming (as previously 16 observed for iPSC reprogramming) we decided to add Lin41 to the core set of 17 reprogramming factors with the goal of further repressing expression of Egr1. Non-18 limb fibroblasts, carrying the GFP reporter under the control of the Prx1 promotor were 19 20 infected with lentivirus transducing Lin28a, Prdm16, and Zbtb16, with or without the addition of Lin41 (Fig. 4A). While we succeeded in converting non-limb fibroblasts into 21 GFP<sup>+</sup> putative rLPCs both in the presence and absence of Lin41(Fig. 4A and S9), the 22 23 cell clusters that resulted from co-infection with Lin41 tended to be larger, and the proportion of pH3-positive cells was significantly higher, than in cultures 24 reprogrammed without this factor (Fig. 4B). As expected, overexpression of Lin41 25

along with the other three reprogramming factors significantly decreased the number
of Egr1 positive cells in comparison with non-limb fibroblasts and empty-virus infected
controls (Fig. 4C). Moreover, cells reprogrammed with Lin41 expressed the same set
of limb progenitor markers as cells reprogrammed by Lin28a, Prdm16, and Zbtb16
alone. (Fig. 4D-I and S9). These results suggest that the inclusion of Lin41 promotes
cell proliferation of the rLPCs without adversely affecting the reprogramming process.

7

## 8 Reprogrammed rLPCs and primary limb progenitors share similar 9 transcriptional profiles

Although the rLPCs that result from driving Prdm16, Zbtb16, Lin28a and Lin41 10 in non-limb fibroblasts show elevated expression of every early limb bud progenitor 11 marker we tested, it was important to establish whether their global transcriptional 12 profile approximated that of legitimate limb progenitors. To that end, we carried out a 13 transcriptome-wide analysis by droplet-based single cell RNA sequencing (scRNAseq). 14 Fibroblasts reprogrammed for 2, 4, 8 or 14 days (enriched for *Prx1*-GFP transgene 15 expression by FACS, Fig. S10) were compared to E9.5 and E10.5 limb progenitors 16 cultured in vitro under identical 3D matrigel conditions for 8 days. In addition, we 17 assayed limb progenitors taken directly from E9.5, E10.0, E10.5 and E11.5/E12.5 18 stage embryos, as well as non-limb fibroblasts (cultured under either 2D or 3D 19 20 conditions) as reference. In total, 74,268 single cell transcriptomes (Fig. S11, Table S1) were subject to dimensional reduction, low dimensional embedding (Brecht et al., 21 2018), graph-based clustering (Traag et al., 2019) and partition-based graph 22 23 abstraction (PAGA) (Wolf et al., 2019).

The cells broadly cluster into seven distinct states, congruent with the different sources of the profiled cells (Fig. 5A, S12A). PAGA shows the relationship of these

1 clusters to one another (Fig. 5A). At one end of this sequence is the cluster containing non-transfected non-limb fibroblasts cultured under 2-D conditions. Non-transfected 2 non-limb fibroblasts (empty vector controls) placed into 3D culture are found in two 3 adjacent clusters, shifted relative to the 2D cultured cells. In contrast, limb progenitors 4 cultured under 3D conditions cluster separately from the non-limb fibroblasts. Limb 5 progenitors taken directly from the embryo (ie. without being cultured *in vitro*) cluster 6 7 separately from the 3D cultured progenitors, with distinct clusters for E9, E10, and E11 8 progenitors.

9 Most Non-limb fibroblasts subjected to reprogramming for 2, 4 or 8 days are 10 found in the same clusters as control non-limb fibroblasts. Strikingly, however, the 3D 11 cultured reprogrammed cells at day 14 completely overlapped with the cultured limb 12 progenitors and were indistinguishable in terms of their transcriptome, showing 13 essentially no differential gene expression and coverage (Fig. 5A, 5C and S13A).

Moreover, this result was obtained whether the cells were reprogrammed with 3 or 4 factors (ie. Lin28a, Prdm16 and Zbtb16, with or without the addition of Lin41) (Fig. 5C); consistent with our finding (above) that Lin41 increases the proliferation of reprogrammed cells, but does not affect their differentiation state.

18 The UMAP pattern we observed can be further understood by reference to genes that characterize each cluster. Markers for non-limb fibroblasts (e.g. Acta2, 19 TagIn) were quickly extinguished for all non-limb fibroblasts grown in 3D Matrigel 20 culture, but only reprogrammed rLPCs upregulated markers similar to the early limb 21 progenitors (eg. Lhx2, Sall4, Tfap2c, Msx1/2, Mycn). Notably, the reprogrammed cells 22 did not upregulate markers of late-stage limb progenitors, such as Sox9 (Fig. 5B). As 23 24 noted above, the 3D cultured limb progenitors (and rLPCs) differ in their transcriptional profile from limb progenitors taken straight from the embryo. Genes differentially 25

expressed by cells under these two conditions include targets of the signaling factors
present in the culture media (Fig. S13B), and genes (such as ribosomal genes and
cell cycle genes) reflecting the high proliferative state of reprogrammed cells *in vitro*(Fig. S11D, E, S13C).

While the 3D cultured limb progenitors fall into a single continuous cluster in 5 this analysis, some distinctions can be observed within the clusters of limb progenitors 6 7 directly taken from the embryo, reflecting differences in the patterning of the cells across the limb bud. Thus, there are subclusters representing Shh-expressing cells of 8 9 the ZPA (zone of polarizing activity), and other genes indicative of cell variation across the anterior-posterior, and proximo-distal axes (Fig. S12D). In this context, the rLPCs, 10 reprogrammed at day 14, mostly show expression of early proximal genes such as 11 proximal Hox genes. In addition, the limb progenitors express either Tbx5 or Tbx4, 12 depending on their fore- or hindlimb origin, while rLPCs weakly express the forelimb 13 marker Tbx5. Taken together, the transcriptome analysis suggests that the 14 reprogrammed cells attain an early forelimb progenitor state, in an active state of 15 proliferation, without evidence of late patterning or differentiation (Fig. 5D). 16

17

## Trajectory analysis reveals the sequence of events during the reprogramming of non-limb fibroblasts into limb progenitor-like cells

Having established that driving the expression of Lin28a, Prdm16, Zbtb16 and Lin41 indeed drives non-limb fibroblasts to a limb progenitor-like state, we wanted to better understand the process by which this occurs. Accordingly, to explore the transcriptional dynamics of the reprogramming, we sub-clustered the cells at higher resolution (Figure 6A, S14B) and turned to optimal-transport analysis (Waddington Optimal Transport, WOT) (Schiebinger et al. 2019). WOT infers the growth rates, and

the ancestor-descendant relationship of cells across time points utilizing the
transcriptome information of individual cells at intermediate time point samples (Fig.
S14A). This in turn is used to construct probabilistic trajectories to specific fates (Fig.
6B, Fig. S14D).

At 14 days after infection and 3D culture, the infected, 3D cultured cells are 5 clustered into four rLPC sub-states (r1, r2, r3, and E9) as well as three transit sub-6 7 states (T1, T2, T3), which are used as fates to construct trajectories (Fig. 6A, B, Fig. S14, S15). The four rLPC substates are distinguished by the relative similarity to the 8 9 E9.5 stage limb progenitors in vivo, where E9 cluster cells grouped together with early E9.5 limb progenitors, with r1/r3 clusters neighboring to the E9 cluster, and r2 cluster 10 close to both E9 and a subset of Osr1+ E12.5 limb progenitors (Fig. S14C). Moreover, 11 the r1 population arises as early as Day 4 after infection and 3D culture, with strong 12 proliferative signature (Fig. S14B, C) whereas r2, r3, and E9 populations are only 13 detected by Day 14. On the other hand, both the acute-phase (A1, A2) as well as 14 transit (T1, T2, T3) clusters display markers of various inflammatory markers, with the 15 A1, A2 cluster showing high expression of the transgene Lin28a (Fig. S14C). 16

The reconstructed rLPC trajectories suggest that by Day 4, the r1 cluster with 17 high proliferative activity arise that dominate the contribution to the subsequent 18 successful reprogrammed state (Fig. 6B, S14D). Comparing the transcriptional 19 20 divergence between the trajectories, the trajectories leading to rLPC states remain close each other until Day 8, whereas they all quickly diverge from others, suggesting 21 that successful reprogramming is determined at early phases of infection and culture 22 23 and those in the successful trajectory remain plastic to a particular rLPC fate (Fig. 6C). Moreover, the reconstructed trajectories provide differentially expressed genes at 24 early time points that are associated to the successful rLPC fate (Fig. 6D, S15A). At 25

acute infection phase, genes countering apoptosis and promoting proliferation are 1 found to be upregulated. Interestingly, the initial level of lentiviral expression as 2 assessed by the counts of Woodchuck Hepatitis Virus Posttranscriptional Response 3 element (WPRE) reads appear to be negatively associated with the rLPC trajectory 4 from others, suggesting that expression of the transgenes was downregulated during 5 the latter process of the reprogramming and may not be required for rLPC production. 6 7 It is followed by the endogenous upregulation of *Lin41* (*Trim71*) as well as genes involved in mRNA stability (Tut4, Pabpc4) and transcription factors Peq3 and Sox11 8 9 that distinguish the successful rLPC trajectories from others. This is true for cells reprogrammed with either 3 or 4 factors (Fig. 6D, Fig. S15A). Lastly, transcription 10 factors involved in patterning appear later at Day 8. Other factors, such as *Prdm16* as 11 well as Zbtb16 were found to be differentially expressed at later phases in 12 reprogramming. 13

14

## 15 Reprogrammed rLPCs differentiate into limb cell types and respond properly to

#### 16 limb patterning cues in vitro

While rLPCs closely resembled limb progenitors at a transcriptional level, it was 17 important to also establish whether they were capable of behaving as such at a 18 functional level. To that end, we first asked if they acquired the capability to differentiate 19 20 into cell types normally found in the developing limb bud. In this instance reprogramming was done without Lin41, as we wanted the rLPCs to be able to freely 21 differentiate once culture conditions were changed. After reprogramming, GFP 22 positive rLPCs were sorted by FACS and cultured in 96 well plastic plates under 23 micromass culture conditions (a well-established in vitro system, used to study the 24 differentiation of limb progenitors) in the presence of the growth factors we optimized 25

1 for keeping limb progenitors undifferentiated. When the cultures became confluent, the growth factors were withdrawn to promote differentiation of the cells, and they were 2 grown for 8 additional days. The chondrogenic capacity of the cells was then analyzed 3 by Sox9 protein and Alcian blue staining, and qPCR for Sox9 (an early 4 chondroprogenitor marker) and Aggrecan1 (Agc1) (a mature chondrocyte marker). We 5 also assessed the capacity to differentiate into connective tissue by looking at 6 7 expression levels of *Scleraxis* (*Scx*), a marker for tendon and ligament precursors (Schweitzer et al., 2001), and Odd-skipped related 2 (Osr2) a gene known to be 8 9 required for specification of joint cells (Gao et al., 2011). Multiple clusters of differentiated reprogrammed cells stained positively with Sox9 and Alcian blue 10 whereas unreprogrammed non-limb fibroblasts did not (Fig. 7A, B). Additionally, 11 transcript levels of Sox9 and Agc1 were upregulated in the differentiated 12 reprogrammed cell cultures, indicating that the rLPCs have acquired chondrogenic 13 potential (Fig. 7C). Moreover, the level of expression of Scx and Osr2 in these 14 differentiated reprogrammed cells was increased (Fig. 7C), indicating that the 15 reprogrammed cells are capable of differentiating into connective tissue cell types as 16 well. 17

We next asked whether the reprogrammed cells would respond to patterning 18 signals in a manner similar to endogenous limb progenitors. The optimized media we 19 20 established for maintaining limb progenitors in culture already contained RA and Fgf8, two signals important for the establishment of proximodistal patterning in the limb buds 21 (Cooper et al., 2011). We therefore examined targets of each of these factors that are 22 23 up-regulated during the normal patterning of the developing limb bud. Meis2, a downstream effector of RA signaling in the proximal limb bud and Dusp6, a readout of 24 Fgf signaling in the distal limb bud, were both activated in the reprogrammed cells (Fig. 25

1 2D). A third important morphogen in the early limb bud is Sonic hedgehog (Shh), a polarizing signal acting along the anterior-posterior limb axis. To examine response 2 to Shh, we assayed the induction of Hoxd13, a key target in the limb bud (Tarchini et 3 al., 2006, Rodrigues et al., 2017). After 24 hours of exposure to Shh, Hoxd13 4 upregulation was observed in a dose-dependent manner in both reprogrammed cells 5 and legitimate limb progenitors whereas it was not seen in unreprogrammed non-limb 6 7 fibroblasts (Fig. 7D). Taken together, the rLPCs appear to have differentiation and patterning potential in vitro similar to those exhibited by endogenous limb progenitors. 8

9

## 10 Reprogrammed rLPCs differentiate into limb cell types in vivo

While these results indicate that rLPCs can respond similarly to limb 11 progenitors under artificial conditions *in vitro*, and generate limb-specific cell types in 12 that setting, it was important to determine whether they could also integrate into a 13 developing limb bud and differentiate appropriately *in vivo*. To test this, we exploited a 14 tetracycline-inducible lentivirus system (Stadtfeld et. al., 2008) (Fig. 4A), so that the 15 reprogramming factors would be under temporal control in vitro, and would be 16 inactivated upon transplantation in vivo. We also needed to be able to follow the 17 transplanted cells as they differentiated, even if they ceased to express GFP from the 18 *Prx1* promoter. To that end, we harvested non-limb fibroblasts from mouse embryos 19 20 carrying a dual reporter. One transgene (*Prx1*-CreER-IRES-GFP) expresses both CreER and GFP in limb progenitors. The GFP activity is therefore lost when the cells 21 differentiate into a state that no longer drives expression from the Prx1 promoter. 22 23 However, a second transgene (R26-CAG-LSL-tdTomato) is irreversibly activated in any cell even transiently expressing CreER in the presence of tamoxifen (Fig. 4A and 24 S9). Thus, derivatives of rLPCs will be marked as red, regardless of whether or not 25

1 they continue to express GFP from the *Prx1* promoter.

rLPCs were generated by introducing Lin28a, Prdm16, Zbtb16 and Lin41 to 2 non-limb fibroblasts via the lentivirus vectors, cultured in the presence of doxycycline, 3 as well as the factors optimized for maintaining limb progenitors (Fig. 4A). These 4 reprogrammed cells were then cultured for 2 days without doxycycline, or the other 5 limb progenitor-maintenance factors, and then the cells were xenografted into limb 6 7 buds of HH20 chicken embryos (Fig. 7E). Despite heterospecific transplantation, grafted authentic limb progenitors derived from E9.5 CAGGS-GFP mice readily 8 9 integrated into chicken wing buds, as previously reported (Fig. 7E) (Izpisua Belmonte et al. 1992). By contrast, almost all mCherry-transfected non-limb fibroblasts were 10 eliminated from the chicken limbs 4 days after they were grafted (Fig. 7E). Similar to 11 the endogenous limb progenitors, the grafted reprogrammed cells stayed within the 12 host limbs over this time period (Fig. 7E). Strikingly, subsets of the tdTomato-positive 13 reprogrammed cells were seen to differentiate into chondrocytes marked by Sox9 or 14 Col2al, and into tenocytes that were stained with an antibody against Col1, similar to 15 legitimate mouse Limb progenitors transplanted into the chicken limbs (Fig. 7F-G). 16 Thus, we conclude that reprogrammed cells are multipotent, are able to participate in 17 limb development, and can generate normal limb tissues in vivo. 18

19

## 20 Reprogramming human fibroblasts into cells resembling limb progenitors

The identification of a set of genes capable of reprogramming embryonic mouse non-limb fibroblasts into rLPCs holds the promise of providing new insight into the specification of the limb bud. In addition, however, this work suggests a potential route towards providing cells that can be used in a therapeutic setting, provided the process can be replicated starting with adult human cells. While a full characterization

1 of human rLPCs would be beyond the scope of this study, we wanted to at least get an indication of whether the reprogramming factors we identified in the murine system 2 would have a similar effect in human fibroblasts. To that end, adult human dermal 3 fibroblasts were infected with lentiviruses transducing our three core reprogramming 4 factors, Lin28a, Pdrm16 and Zbtb16, and were then placed in 3D culture under limb 5 progenitor maintenance conditions. After 18 days, cell aggregates emerged, 6 7 resembling plated mouse limb bud cells as well as those seen when reprogramming mouse non-limb fibroblasts (Fig. S16A). We examined the expression of several limb 8 9 progenitor markers (SALL4, LHX2 and NMYC) as well as EGR1 in these cells. All three limb progenitor markers were up-regulated in comparison with control human 10 dermal fibroblasts, while EGR1 expression was diminished (Fig. S16B, C). Of note, 11 the expression patterns of NMYC and EGR1 were mutually exclusive (Fig. S16C). 12

To get a more complete understanding of the transcriptional changes resulting 13 from the reprogramming of the human dermal fibroblasts, we undertook a single-cell 14 transcriptomic analysis of the human cultures infected with the Lin28a, Pdrm16, 15 Zbtb16 lentiviruses, with or without co-infection of Lin41. Cells cultured in the 3D limb 16 progenitor maintenance conditions for 18 days were compared to control human 17 dermal fibroblasts grown in the same conditions (Fig. S17A). These data further 18 support the down-regulation of dermal fibroblast markers and up-regulations of limb 19 20 progenitor markers (Fig. S17B). A limitation of using human cells is the lack of legitimate embryonic human limb progenitors for comparison. Therefore, the human 21 reprogrammed and control samples were aligned with the mouse single cell 22 23 transcriptome embedding. This analysis indicates that the reprogrammed human dermal fibroblasts aligned with the early mouse limb progenitor state (Fig. S17C). 24

Finally, to get preliminary indication of whether the reprogrammed human

rLPCs have some of the same differentiation potential as limb bud cells, we conducted 1 xenograft experiments in which the dissociated putative reprogrammed cells were 2 transplanted into chicken limb buds. Unlike mouse non-limb fibroblasts, the grafted 3 human dermal fibroblasts were able to engraft in the chicken limbs, however, they 4 were completely excluded from cartilage elements and showed no Sox9 expression 5 (Fig. S16D). By contrast, a fraction of the grafted reprogrammed cells integrated into 6 7 Sox9<sup>+</sup> cartilage (Fig. S16D), implying that the cells could differentiate into chondrocytes. The percentage of transplanted cells incorporated into the cartilage 8 9 seemed to be much lower than with the mouse rLPCs. However, that was to be expected as, unlike the transgenic mouse cells, human dermal fibroblasts lacked the 10 *Prx1*-GFP reporter, and hence the cultures could not be enriched for reprogrammed 11 cells by FACS prior to transplantation. Taken together, these results suggest that 12 human dermal fibroblasts are indeed transformed by the same reprogramming factors 13 as in the mouse, towards a state that at least has characteristics in common with limb 14 progenitors. 15

16

### 17 **Discussion**

In this study, we have established long-term culture conditions to maintain limb progenitors, identified factors that are sufficient to reprogram non-limb fibroblasts into rLPCs, and validated their similarity to limb progenitors via multiple criteria.

21

22 **Optimized 3D culture conditions for long-term maintenance of limb progenitors** 23 Identifying adequate culture conditions for maintaining stem cells being targeted is 24 known to have been a key factor in the success of other reprogramming studies. For 25 instance, the Yamanaka factors failed to reprogram mouse embryonic fibroblasts to

iPSCs in the absence of leukemia inhibitory factor (LIF) and feeder cells (Takahashi 1 and Yamanaka, 2006). Since our previous culture condition for limb progenitors 2 (Cooper et al. 2011) was effective only for the short term, we sought to optimize the 3 conditions for long-term maintenance of limb progenitors. Ultimately, we found that a 4 cocktail of CHIR90021 (a GSK3ß antagonist) Fgf8, RA, SB431542 (a Bmp/TGFß 5 inhibitor) and Y-27632 (a Rock inhibitor) will maintain limb progenitors in a HA or 6 7 Matrigel 3-D matrix for an extended period of culture. Although RA is necessary to keep cells in the progenitor state through activation of limb progenitor genes such as 8 9 Meis1/2 and by blocking chondrogenic differentiation (Cooper et al., 2011), RA can also induce apoptosis as seen in interdigital mesenchyme. The RA-induced apoptosis 10 is partially mediated by Bmp7 (Dupé et al., 1999), thus TGFβ/BMP antagonist 11 SB431542 may not only inhibit differentiation of limb progenitors but also block cell 12 death during culture. In addition, it is noteworthy that the endogenous RA 13 concentration is higher in the anterior part of the embryo than that in the posterior 14 region and thereby promotes induction of *Tbx5*, but not *Tbx4*, during forelimb initiation 15 (Nishimoto et al., 2015). It is therefore likely that RA also contributes to upregulation 16 of Tbx5 in rLPCs during reprogramming, and is thus responsible for the forelimb-like 17 characteristics of these cells. 18

19

## 20 Possible roles of the reprogramming factors

Given that overexpression of Lin28a alone is capable of inducing *Prx*GFP and Sall4, we consider Lin28a as a central reprogramming factor. By contrast, exogenous Tbx5 and Nmyc were dispensable for rLPC reprogramming despite their necessity for normal mouse limb development (Agarwal et al., 2003). Intriguingly, *Lin28, Sall4, Nmyc, Tbx5* and *Lin41*, mRNAs that are transcribed in early limb progenitors, are

1 suppressed by members of the *let-7* miRNA family in other contexts, including the regulation of embryonic stem cells, iPSC reprogramming, and during cardiogenesis 2 (Wang et al., 2013). Thus, there is a possibility that Lin28a indirectly upregulates 3 expression of limb progenitor-specific genes globally, by blocking let7 miRNA activity, 4 thereby triggering rLPC reprogramming. We also find that Lin41 promotes mouse 5 rLPC proliferation and maintenance in a progenitor state. In our scRNAseg analysis, 6 7 endogenous Lin41 upregulation was an early gene expression signature at the time when highly proliferative r1 subpopulation arise, and a lower level of endogenous 8 9 Lin41 expression at later time points in a subset of rLPCs lacking Lin41 overexpression were associated with rLPC subpopulation which showed transcriptomic similarity to 10 later phase limb bud cells (r2), whereas rLPC trajectories that maintained high level of 11 Lin41 expression resulted in rLPC fates that showed transcriptional similarity to early 12 limb bud cells. A similar result was seen with reprogrammed human dermal fibroblasts. 13 In scRNAseq analysis, Lin41-overexpressing cells were partially aligned with E9.5 14 mouse limb progenitors, whereas reprogrammed cells without Lin41 were separated 15 from the early limb progenitors, suggesting a role for Lin41 in keeping reprogrammed 16 cells in the undifferentiated early limb progenitor state. Mechanistically, Lin41 is likely 17 to inhibit translation of Egr1, but not mRNA transcription, given that transcript levels of 18 *Egr1* are not decreased in Day 14 mouse and Day 18 human reprogrammed cells 19 20 according to our scRNAseg analysis. Lin41 is also known to ubiquitinate the tumor suppressor p53 in murine embryonic stem cells, thereby antagonizing cell death and 21 differentiation pathways (Nguyen et al., 2017). As suppression of p53 promotes iPSC 22 23 reprogramming (Kawamura et al., 2009), perhaps Lin41 potentiates rLPC reprogramming through its ubiquitinase activity. This raises the possibility that there is 24 a "let7 barrier" that may hamper rLPC reprogramming as seen in iPSC 25

reprogramming (Worringer et al., 2013). In that context, *let-7* miRNAs suppress
 stemness factors including *Oct4*, *Nanog*, *Sox2* (Melton et al., 2010), and *Myc* and
 *Lin41* (Worringer et al., 2013).

In concert with Lin28a, Prdm16 and Zbtb16 are each capable of inducing Lhx2 4 expression in non-limb fibroblasts. The role of Prdm16 in limb development has not 5 been previously characterized. Prdm16 contains protein interacting zinc-finger and 6 7 histone lysine methyltransferase domains and is known as a crucial regulator of adipose development, with implications for several processes including energy 8 9 homeostasis and glucose metabolism (Chi and Cohen, 2016). Considering that accelerated metabolism is a key driver for iPSC reprogramming and tumorigenesis, 10 and rapid proliferation is one of the hallmarks of early limb progenitors (Spyrou et al., 11 2019), Prdm16 may contribute to rLPC reprogramming by enhancing the metabolic 12 status of non-limb fibroblasts in addition to inducing limb progenitor-specific genes 13 such as Lhx2. Unlike Prdm16, the involvement of Zbtb16 in limb development has 14 been described previously. Zbtb16, which is also a zinc-finger transcription factor, 15 regulates the expression of several Hox genes, including Hox10, downstream of Sall4, 16 and is required for proximal development of the mouse limb (Barna et al., 2000). 17 Whether Zbtb16 similarly controls Hox expression during rLPC reprogramming is a 18 topic for future investigation. 19

20

## 21 Potential of rLPCs for clinical application

As rLPCs have the potential to differentate into chondrocytes and connective tissues,
rLPCs could, in principle, be harnessed for regenerative therapies in the future.
Previously, endogenous limb progenitors and iPSC-derived limb progenitor-like cells
have been shown to enhance regenerative processes when transplanted into

amputated frog limbs and mouse digit tips, respectively (Lin et al., 2013; Chen et al., 1 2017). 3D spheroids of limb progenitor-like cells also can be induced from mouse 2 embryonic stem cells (Mori et al., 2019). None of these studies, however, including our 3 own, have demonstrated that induced or reprogrammed limb progenitors have the 4 capacity, on their own, to give rise to a limb-like structure, patterned along various 5 axes and containing appropriate differentiated tisssues. In principle, this can be tested 6 7 by constructing a "recombinant limb", in which dissociated limb mesenchyme (or, in principle, rLPCs) are pelleted, and packed into an empty shell of limb ectoderm, and 8 9 grafted onto a host embryo (Zwilling, 1964, Ros et, al., 1994). Such recombinant limbs made with limb progenitors make well formed limb-like structures. However, as the 10 recombaint limb assay is only feasible with avian embryos, a recombinant system 11 using reprogrammed avian cells will be required. 12

Our study may also open the way to *in vivo* direct rLPC reprogramming (Zhou 13 et al., 2008). By overexpressing the reprogramming factors in dermal fibroblasts at an 14 amputation site of a human limb, cells might be reprogrammed towards a limb 15 progenitor state, thereby potentiating the *in situ* development of a limb-like structure. 16 Of note, two of the reprogramming factors, *Lin28* and *Prdm16* are re-expressed in 17 blastema of regenerating appendages in other systems (Rao et. al., 2009; Yoshida et. 18 al., 2020). While such the rapeutic applications will require a great deal of further work, 19 20 the study described here provides a more immediate platform for interrogating the molecular control of the limb progenitor state. 21

22

## 23 Acknowledgements

We thank Drs. Gufa Lin (University of Minnesota), Yasu Kawakami (University of
Minnesota), Johanna Kowalko (Florida Atlantic University), Jessica L. Whited (Harvard

Medical School) and Daisuke Saito (Kyushu University) for helpful discussions. We also thank the Single Cell Core (Harvard Medical School), the Flow Cytometry Core (Brigham and Women's Hospital), and the Biopolymers Facility (Harvard Medical School) for providing experimental platforms used in this work. This work was supported by NIH grant HD03443 (to C.J.T.). Y.A. was a recipient of fellowships from the Naito foundation and JSPS for research abroad. E.L. was a recipient of a fellowship from the NSF 1612264.

8

## 9 Author Contributions

Y.A., C.L., A.R. R., C. C., R. R. T. and E. G. L. conducted the experiments; Y. A., C. L.,
A. R. R., C. C., R. R. T., P. T., D. C and J. G. analyzed the data; J. P. V. contributed
new reagents; C.E.S., J.G.S., O.P., and C.J.T. supervised the work; Y.A., C.L., and
C.J.T. wrote the first draft; and all authors revised the manuscript.

14

## 15 **Declaration of Interests**

16 The authors declare no competing financial interests.

17

## 18 Figure legends

19 **Figure 1** 

## 20 Overexpression of the factors that are present specifically in the limb bud 21 induces expression of limb progenitor genes in non-limb fibroblasts

(A) Optimization of culture conditions for forelimb (FL) progenitors from *Prx1*-GFP
mouse embryos (*Prx*GFP<sup>+</sup> LPs) by using hyaluronan (HA)-based hydrogels. The
cultured LPs were stained with antibodies for GFP (green), Lhx2 (magenta) and Sall4
(white). Serum media was DMEM containing 10% FBS, and CFRSY media contained

1 Chir99021 (3 µM), Fgf8 (150 ng/ml), Retinoic acid (25 nM), SB431542 (5 µM) and Y-27632 (10 µM). (B) Increasing ratio of cell number. Cell numbers in Day0 samples of 2 each condition were counted immediately after seeding, and were considered as ratio 3 1. (C) Percentages for PrxGFP/Lhx2/Sall4-triple positive cells in cultures. (D) 4 Schematics of HH stage 15 and HH19 chicken embryos. Regions of embryos that 5 were used for transcriptomic analyses are labeled. (E) Differential expression analyses 6 7 (MA-plot) of core gene set. Limb expression (average of FL and hindlimb [HL]) over neck or flank expression. Labeled points indicate genes with greater than two-fold 8 9 overexpression in limb tissue. (F) Lin28a mRNA expression levels in FL, flank and HL of E9.5 mouse embryos were measured by qPCR (n = 6 for each). (G) Diagrams 10 illustrating procedures of the reprogramming experiment. Retrovirus particles carrying 11 each factor of 18 candidates were pooled and used to infect non-limb PrxGFP-12 negative fibroblasts (NonLFs) at Day0. After infection, the media was replaced with 13 CFRY (Day2-4), subsequently with CFRSY (Day4-14). The infected NonLFs were 14 seeded in HA-gels at Dav4. (H) The cells infected with no virus or 18 viruses carrying 15 candidate factors were visualized by DAPI (blue). Dashed lines indicate outer edge of 16 the hydrogel. Induced *Prx*GFP signals were seen in cell clusters (yellow arrowheads). 17 (I) Magnified images of the cell clusters. Sall4 proteins were observed in PrxGFP 18 positive cells. (J) Relative expression levels of GFP, Fgf10, FgfR2c, Msx2, Hoxd9, 19 20 *Lhx9*, *Meis2*, *Dusp6* and *Axin2* were quantified by qPCR (n = 4 for NonLFs, n = 3 for +18 factors). \*\*\*\**p* < 0.0001, one-way ANOVA. Error bars represent SD. Scale bars, 21 100 µm in (A) and (I), 1 mm in (H). 22

23

24 Figure 2

25 Identification of a minimal set of the reprogramming factors essential for

## 1 imparting limb progenitor like-properties on non-limb fibroblasts

2 (A) Efficiency of *Prx*GFP induction was estimated as a GFP score by measuring GFP positive area per DAPI area. In 18-1 factor assay, each factor was withdrawn from the 3 pools one by one (n = 4 gels each; see also Fig. S5). GFP score for the 18 factor-4 group was 10.57. Seven factors (Hoxd10, Zbtb16, Lhx2, Prdm16, Etv4, Tfap2a and 5 Lin28a) that contributed to *Prx1*-GFP induction were tested for further screening as 6 described in Fig. S6. The measured DAPI- or Prx1-GFP-positive area was 7 pseudocolored in red. (B, C) GFP scores of Lin28a+1 factor assay. Combination of 8 9 Lin28a with Prdm16, Zbtb16 or both (+PZL) yielded the highest GFP score and induced Lhx2 (magenta) and Sall4 (white) as well as PrxGFP (green) (n = 3 each). (D, 10 E) qPCR for LP markers using controls (No virus), cells reprogrammed by 11 overexpression of PZL, and LPs from E9.5 *Prx1*-GFP reporter embryos (n = 3 each in 12 D, n = 4 each in E). GFP-positive reprogrammed cells and LPs were FAC-sorted 13 beforehand. Error bars represent SD. Scale bars, 100 µm in (C), 1mm in (A). 14

15

16 Figure 3

## Misexpression of EGR1 disturbs limb bud outgrowth and induces precocious differentiation of limb progenitor

(A) Cross sections of E9.5 and E10.5 mouse FL buds stained with Egr1 (green) and
Sall4 (magenta) antibodies. (B) E9.5 mouse LPs and NonLFs were cultured on petri
dishes for 36 hrs in the presence of CFRSY or 10% FBS (serum), then were stained
with an Egr1 antibody. (C) Plasmids carrying H2BmCherry-ires-ZsGreen1 (Control) or
human EGR1-ires-ZsGreen1 (EGR1-OE) were electroporated into the chicken
forelimb buds. Electroporated HH21 embryos were analyzed. (D) Overexpression of
EGR1 inhibited lateral movement of limb mesenchyme. Relative length of the

electroporated limbs to contralateral ones was measured (n = 14 limb buds each). (E) A mitotic marker phospho-Histone H3 (pH3) was detected by immunostaining in control and EGR1-electroporated limbs. pH3 positive cells per ZsGreen<sup>+</sup> cells were counted (n = 6 each). (F) Immunostaining for Sox9 and Collagen I (Col1) in EGR1electroporated or contralateral control limbs. \*\*p < 0.01, \*\*\*p < 0.001, a 2-tailed unpaired Student's *t* test. Error bars represent SD. Scale bars, 100 µm in (A), (B), (E), 200 µm in (C), (D), (F).

8

### 9 Figure 4

## 10 Addition of Lin41 to PZL stimulates proliferation of the rLPCs

(A) Schematics illustrating the modified reprogramming experiment. GFP/tdTomato-11 negative non-limb fibroblasts from Prx1-GFP/tdTomato reporter mice (Prx1-GFP-ires-12 CreER; CAG-LSL-tdTomato [Ai9]) were infected with tetO-lentiviruses carrying PZL 13 and Lin41. Lentivirus carrying no transgene was used as Control. Doxycycline was 14 administered during the culture. The cells overexpressing PZL or PZLL (PZL + Lin41) 15 were seeded on Matrigel, and *Prx*GFP/tdTomato signals were examined at Day14. 16 See also Fig. S9. (B) The number of pH3 signals was counted in E9.5 FL, Control, 17 PZL- and PZLL-reprogrammed cells (n = 6 each). (C) Egr1 proteins were stained in 18 NonLFs, Control and PZLL-reprogrammed cells. The number of Egr1 positive cells 19 20 was quantified (n = 6 each). (D-I) LP markers were detected in the reprogrammed cells. E9.5 mouse FL and NonLFs were used as positive and negative control, 21 respectively. In the MERGE panels for E9.5 FL and NonLFs, DAPI and signals for a 22 23 target protein were merged. For Control, +PZL and +PZLL groups, DAPI, GFP, tdTomato and signals for the target were merged. Lhx2 (D), Sall4 (E), Nmyc (F), 24 Tfap2c (G), Msx1/2 (H) and Meis1/2 (I) were induced in both PZL and PZLL 25

reprogrammed cells. \*\**p* < 0.01, \*\*\*\**p* < 0.0001, one-way ANOVA. Error bars represent</li>
 SD. Scale bars, 100 μm in (B-E).

3

### 4 Figure 5

## Single-cell RNA-seq analyses reveal global transcriptomic similarity between the rLPCs and endogenous limb progenitors

7 (A) Left panel: UMAP plot of NonLFs, limb progenitors (E9.5, E10.5, E11.5+), limb progenitors cultured for 8 days in matrigel culture (E9.5-E10.5 (3D)), cells infected with 8 9 empty control virus (Empty) and reprogramming factors (R) sampled at different time points (D=days after culture). Overlaid are cluster labels by graph-based clustering 10 (leiden, resolution=0.2), with edges between clusters from PAGA analysis. The 11 thickness of edges represents the connectivity between clusters. Only the strong 12 connection above threshold (0.05) were shown. Right panel: Split of cells by sample 13 source and clusters. (B) Left panel: Expression of selected genes in UMAP 14 coordinates. Right panel: Dot plot of select genes by clusters. (C) Volcano plot 15 comparing PZL-infected/PZLL-infected rLPCs to 3D cultured LPCs, in rLPC/LPC (3D) 16 cluster (Leiden, resolution=0.2). Adjustment of p-values were performed by 17 pseudobulk aggregation of expression data by independent samples that were grown 18 in 3D culture condition and comprise more than 100 cells for the rLPC/LPC (3D) cluster, 19 20 using Benjamini-Hochberg adjustment (PZL: n=5, PZLL: n=3, primary: n=2). Red dotted line is threshold of adjusted p-value=0.1. Only comparison between 3D cultured 21 LPCs and PZLL-infected cells have five genes above the threshold, circled and labeled. 22 23 All genes more than 20 log fold changes, likely due to zero counts in one contrast, are put into infinity for better visualization. Right: UMAP plot showing the cluster and cells 24 used for differentially expressed gene analysis in (C). Bottom panel: Dot plot of 25

patterning genes in the rLPC/LPC (3D) cluster. All expression level in natural-log
transformed UMI counts normalized by the total UMI counts per cell, maximal
expression. PZL refers to Prdm16+Ztbt16+Lin28a (3-factor lentiviral expression).
PZLL refers to Prdm16+Ztbt16+Lin28a+Lin41(Trim71) (4-factor lentiviral expression).

5

6 Figure 6

## 7 Optimal transport analysis delineates transitions of reprogramming of the 8 rLPCs from non-limb fibroblasts

9 (A) Left panel: UMAP plot with fine clusters (Leiden clustering, resolution=0.4), overlaid with edges between clusters from PAGA analysis. The thickness of edges 10 represents the connectivity between clusters. Only the strong connection above 11 threshold (0.1) were shown for clarity. Right panel: the composition of each clusters 12 according to the sample source in stacked column graph. The clusters are roughly 13 ordered from the initial starting material (NonLFs) to the later stages of limb progenitor 14 cells. (B) Alluvial (flow) plot based on the transition matrix inferred by Waddington 15 Optimal Transport (WOT) analysis. WOT analysis generates temporal couplings 16 between sets of cells between time points. The initial width of each alluvial segment 17 represents the probability of transition of the group of cells from the earlier state to 18 later state. The final width incorporates the estimated growth rate of the destination 19 20 cell cluster. Thus, wider width than the initial starting point represent expansion (proliferation) after transition, whereas narrower width means contraction (cell death 21 or stasis) to the next time point. All alluviums are colored by the final (Day 14) fate of 22 23 the cells (See also Fig. S14D for individual highlights). (C) The fraction of transcriptional divergence accrued at intermediate time points between trajectories 24 towards final fate. Each lines represent a comparison between two distinct trajectories, 25

grouped and colored by the final fate of the two populations. (D) Changes of mean
expression levels of individual genes at a given time point weighted by the probability
of the final fate inferred by WOT. All expression level in natural-log transformed UMI
counts normalized by the total UMI counts per cell. (E) Schematic diagram of
reprogramming. PZL refers to Prdm16+Ztbt16+Lin28a (3-factor lentiviral expression).
PZLL refers to Prdm16+Ztbt16+Lin28a+Lin41(Trim71) (4-factor lentiviral expression).

7

### 8 Figure 7

## 9 The rLPCs exhibit differentiation potency towards chondrocytes and tenocytes

(A, B) Micromass cultures to test in vitro chondrogenesis capacity of the 10 reprogrammed cells. Sox9 or Alcian blue positive clusters emerged from the 11 reprogrammed cells. The number of Alcian blue positive clusters in NonLFs and the 12 reprogrammed cell groups were counted (n = 6 wells for each). (C) gPCR analyses 13 for Sox9, Aggrecan1 (Agc1), Scleraxis (Scx) and Osr2 (n = 6 each). FL cells from E9.5 14 *Prx1*-GFP embryos were micromass-cultured as well and used as positive controls. 15 (D) Shh ligand and Hoxd13 gene expression titration curves. Samples were treated 16 for 24 hrs with varying levels of Shh ligand (0, 0.5, 1 and 2 ng/ $\mu$ l; n = 3 for each group 17 and time point). (E) E9.5 CAG-GFP mouse LPs, NonLFs expressing mCherry and 18 FAC-sorted tdTomato PZLL-reprogrammed cells were transplanted into HH20 (E3.5) 19 20 chick FL buds. 4 days after the grafting, the limbs were harvested at HH32 (E7.5). The grafted GFP-LPs and tdTomato-reprogrammed cells were seen in the HH32 limbs 21 (yellow arrowheads), while mCherry-NonLFs were not detectable (a black arrowhead). 22 23 (F-H) The harvested HH32 limbs were sectioned and stained with Sox9 (F), Collagen II (Col2, G) and Col1 (H) antibodies. A fraction of the grafted LPs (n = 7) and tdTomato-24 reprogrammed cells marked by yellow arrowheads (n = 3) were positive for each 25

marker. \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, \*\*\*\*p < 0.0001, a 2-tailed unpaired Student's *t* test. Error bars represent SD. Scale bars, 100 µm in (F), 1 mm in (A), (B, the lower bar), (E), 2mm in (B, the upper bar).

4

## 5 Supplemental figure 1

# Optimization of conditions for culturing endogenous mouse limb progenitors, Related to Figure 1

(A) Limb progenitors (LPs) from forelimbs (FL) of E9.5 CAG-GFP mouse embryos
were cultured in either 10% FBS/DMEM (Serum condition) or media supplemented
with Chir99021 (3 μM), Fgf8 (150 ng/ml), Retinoic acid (25 nM) (CFR condition) for 4
days. (B) LPs from E9.5 *Prx1*-CreER-ires-GFP mouse embryos were dissected out
and cultured for 10 days under Serum, CFR and CFRSY (CFR plus Y-27632 and
SB431542) conditions. The cells were stained by using GFP (green), Lhx2 (magenta)
and Sall4 (white) antibodies. Scale bars, 100 μm in (B), 200 μm in (A).

15

## 16 Supplemental figure 2

Chicken limb progenitors cultured in CFRSY/HA-gel condition maintain 17 differentiation potentials into chondrocytes and tenocytes, Related to Figure 1 18 (A) LPs from HH18 GFP chicken embryos were cultured in hyaluronan (HA)-based 19 20 hydrogels, in the presence of CFRSY for 8 days, and then they were dissociated and transplanted into HH20 chick FL buds. The grafted limbs were harvested at HH32, 4 21 days after transplantation, and sectioned followed by staining for Sox9. The grafted 22 23 cells were seen in Sox9-positive cartilage (yellow arrowheads). (B) The grafted GFP cells were stained with Collagen I antibody (yellow arrowheads). (C) The cells were 24 MHC, a muscle marker, negative (black arrowSheads), but closely associated with 25

1 MHC-positive muscles (red). Scale bars, 100 µm in (A-C).

2

## 3 Supplemental figure 3

## 4 Expression of limb progenitor marker genes is maintained in mouse LPs

## 5 cultured under CFRSY/Matrigel condition, Related to Figure 1

6 (A) PrxGFP<sup>+</sup> LPs were cultured on 50% Matrigel in media supplemented with CFRSY

7 for 8 days. *Prx*GFP, Lhx2 and Sall4 were immunostained and the number of the triple

8 positive cells were counted (n = 6 each). (B) Percentages for *Prx*GFP/Lhx2/Sall4-triple

9 positive cells in cultures at Day8. (C) Other LP markers, Nmyc, Tfap2c and Msx1/2,

10 were also stained. Error bars represent SD. Scale bar, 100 µm in (A).

11

## 12 Supplemental figure 4

## Transcriptomic comparison of the early limb bud to neighboring lateral plate mesodermal tissue, Related to Figure 1

(A) Principal component analysis of five transcriptomic data sets. FL and HL bud
 expression values cluster closely together. Separation of other three data sets occurs
 across principal component 1 (PC1) and principal component 2 (PC2). (B) Top five
 most statistically significant enriched gene ontology classifications for top 100 genes
 associated with PC1 and PC2.

20

## 21 Supplemental figure 5

22 Whole-mount views of HA-gels with 17 factors overexpressing cells (18-1

## 23 dropout assay), Related to Figure 2

Each factor was withdrawn from the pools one by one to see which factor was critical

for *Prx*GFP induction. Scale bar, 2 mm.
1

#### 2 Supplemental figure 6

## 3 Lin28a is a key factor for induction of limb marker genes, Related to Figure 2

(A) 7 (Hoxd10, Tfap2a, Lhx2, Etv4, Prdm16, Zbtb16, and Lin28a) -1 factor dropout 4 assay showed that every factor from the pools was critical for *Prx1*-GFP induction. 5 When Lin28a was removed, the GFP score was the lowest and Sall4 proteins were 6 7 not detected. (B) 7-2 dropout assay was performed. Note that GFP scores were decreased when Lin28a and one additional factor were withdrawn from the pools. (C) 8 9 Single factor assay, in which only one factor was used to infect NonLFs, was conducted. Lin28a yielded the highest GFP score, and induced expression of Sall4, 10 bsut not Lhx2. Error bars represent SD. Scale bars, 100 µm in (A), (C). 11

12

#### 13 Supplemental figure 7

#### 14 Size reduction occurs after the reprogramming, Related to Figure 2

15 (A) FACS profiles of NonLFs, PZL-reprogrammed cells and LPs from E9.5 *Prx1*-GFP 16 embryos. FSC-A indicates surface area of cells. (B) Area of DAPI signals of Control 17 (no virus condition), PZL-reprogrammed cells, or 3D cultured limb progenitors was 18 measured (n = 50 cells each). \*\*\*\*p < 0.0001, one-way ANOVA. Error bars represent 19 SD. Scale bar, 100 µm in (B).

20

#### 21 Supplemental figure 8

## 22 Expression analyses of *Egr1* mRNA in the chicken embryos and Egr1 proteins

#### 23 in the mouse forelimb, Related to Figure 3

24 (A) mRNA expression patterns of Sall4, Lin28a, Lin41 and Egr1 at the FL forming

region of HH15 and FL buds of HH19 chicken embryos. *Egr1* was not present at HH15

(a black arrowhead) while it was detected at HH19 (a yellow arrowhead). (B) Egr1
 (green) and MHC (red) were visualized in E13.5 mouse FL. Egr1 signals were
 localized at the end of myofibers as marked by yellow arrowheads. Scale bar, 500 μm
 in (B).

5

## 6 Supplemental figure 9

7 Expression analysis for *Prx1*-GFP/tdTomato in the reprogrammed cells, Related
 8 to Figure 4 and 7

9 Schematic representation of the strategy to induce *Prx1*-GFP and tdTomato by 10 reprogramming. GFP and tdTomato expression were investigated in a cross section 11 of an E9.5 *Prx1*-GFP/tdTomato reporter embryo, NonLFs, Control cells, PZL- and 12 PZLL-reprogrammed cells. Control cells were infected with viruses carrying no 13 transgene. Control, PZL- and PZLL-reprogrammed cells were cultured for 14 days as 14 depicted in Fig. 4A. Scale bar, 100 µm.

15

#### 16 Supplemental figure 10

## 17 Representative FACS profiles of samples used for scRNA-Seq analyses, Related 18 to Figure 5

(A) Mouse cells transfected with PZL, cultured in CFRSY/HA condition. (B) Mouse
cells transfected with no transgene (empty viruses), cultured in CFRSY/HA condition.
(C) Fresh E9.5 LPs from *Prx1*-GFP mice. (D) mouse cells transfected with PZLL,
cultured in CFRSY/Matrigel condition. (E) Mouse cells transfected with PZL, cultured
in CFRSY/Matrigel condition. (F) Mouse cells transfected with no transgene (empty
viruses), cultured in CFRSY/Matrigel condition. (G) E9.5 primary mouse cells cultured
in CFRSY/Matrigel condition. (H) Human cells transfected with PZLL, cultured in

1 CFRSY/Matrigel condition. (I) Human cells transfected with PZL, cultured in 2 CFRSY/Matrigel condition. (J) Human cells transfected with no transgene (empty 3 viruses), cultured in CFRSY/Matrigel condition. DAPI and DRAQ5 were used to mark 4 dead and vital cells, respectively. The *Prx*GFP+ cells were sorted as reprogrammed 5 cells. (m): mouse cells, (h): human cells. PZL refers to Prdm16+Ztbt16+Lin28a (3-6 factor lentiviral expression). PZLL refers to Prdm16+Ztbt16+Lin28a+Lin41(Trim71) (4-7 factor lentiviral expression).

- 8
- 9

## 10 Supplemental figure 11

## 11 Aggregate cell-level statistics, Related to Figure 5

(A) Cell counts per library, (B) UMI counts per cells, (C) Genes per cell, (D) 12 mitochondrial fraction (UMI counts of mitochondrial genes divided by the total UMI 13 counts), (E) ribosomal gene fraction (UMI counts of ribosomal genes divided by the 14 total UMI counts). 10X Genomics v3 and InDrop technology have very different RNA 15 capture rate, thus UMI counts as well as gene coverage. Therefore, each statistic was 16 separated into the two technological batches. Matrigel-related samples (3D) were 17 processed with 10X Genomics v3 technology, whereas the hyaluronan (HA)-related 18 reprogramming samples were processed with InDrop technology. Red dots represent 19 20 the median values for each sample annotation. PZL refers to Prdm16+Ztbt16+Lin28a (3-factor lentiviral expression). PZLL refers to Prdm16+Ztbt16+Lin28a+Lin41(Trim71) 21 (4-factor lentiviral expression). 22

23

## 24 Supplemental figure 12, Related to Figure 6

## 25 Expression of the reprogramming genes and *PrxGFP* in the UMAP

(A) Four panels highlight cells from specified sample sources, with color contours
 representing the density of the corresponding sample source.

(B) Expression of PZLL genes, select limb patterning genes and fraction of transgene 3 expression in UMAP coordinates. For specific genes, the values are log-transformed, 4 UMI counts normalized by the total UMI counts of a cell. Fraction of transgenes 5 represent the total number of UMIs attributed to the potential transgenes (includes 6 7 EGFP, Woodchuck Hepatitis Virus Posttranscriptional Response element (WPRE) counts as well as human Lin41 (hLin41) UMI counts, with the addition of Prdm16, 8 9 Ztbt16, Lin28a UMI counts, where the endogenous to transgene cannot be distinguished) to total UMI counts for a given cell and the maximum is 1. Maximum 10 value for a given coordinate. 11

(C) Dot plot of patterning genes in all clusters. All expression level in natural-log
transformed UMI counts normalized by the total UMI counts per cell, maximal
expression. PZL refers to Prdm16+Ztbt16+Lin28a (3-factor lentiviral expression).
PZLL refers to Prdm16+Ztbt16+Lin28a+Lin41(Trim71) (4-factor lentiviral expression).

- 16
- 17

#### 18 Supplemental figure 13, Related to Figure 5

#### 19 The effect of 3D culture condition by comparing LPCs in 3D cultured condition

#### 20 for 8 days to LPCs harvested directly from corresponding stages

(A) Left panel: Volcano plot comparing cultured limb progenitors (LPCs) and primary
LPCs from rLPC/LPC (3D), LPC (E9), and LPC (E10) clusters (Leiden, resolution=0.2).
Adjustment of p-values were performed by pseudobulk aggregation of expression data
by independent E9.5-E10.5 samples that comprise more than 100 cells for the cluster
1, 4, 7 using Benjamini-Hochberg adjustment (3D cultured condition: n=2, Immediately

harvested: n=7). Red dotted line is threshold of adjusted p-value=0.1. All genes more 1 than 20 log fold changes, likely due to zero counts in one contrast, are put into infinity 2 for better visualization. Right panel: UMAP plot showing the cluster and cells used for 3 differentially expressed gene analysis in (A). Left panel: Bar plot of geneset enrichment 4 analysis of differentially expressed gene lists from (A). k/K is the fraction of genes of 5 a given gene set overlapping with the differentially expressed gene lists (cut-off 6 7 adjusted p-value = 0.1). Right panel: -log10 of FDR q-value for the overlap. Select gene sets from MsigDB (Subramanian et al. 2005; Liberzon et al. 2011). (C) Gene 8 9 Ontology (GO) term enrichment analysis of differentially expressed gene lists from (A), with Top 20 GO terms arranged by FDR q-value. 10

11

#### 12 Supplemental figure 14, Related to Figure 6

## High-resolution clustering of scRNA-seq cells for Waddington Optimal Transport (WOT) analysis

(A) UMAP plots of infected and 3D cultured cells used for scRNA-seg analysis split by 15 sample date and the type of infection. All primary cells were excluded. (B) Cell cycle, 16 Apoptosis gene set z-scores calculated for Waddington Optimal Transport (WOT) 17 analysis with other Gene Ontology (GO) term gene sets and independently calculated 18 G2M/S Scores and ribosomal fractions for reference. GO FL MORPHO (Embryonic 19 20 forelimb morphogenesis, GO: 0035115), GO JOINT DEVO (Embryonic skeletal joint development, GO: 0072498), GO TENDEON DEVO (Tendon development, GO: 21 0035989), GO CHONDRO DEVO (Chondrocyte development, GO:0002063). (C) 22 23 Left panel: UMAP plot with cells colored by high-resolution leiden cluster annotation (resolution=0.4) with circled labels positioned at the center of corresponding clusters. 24 Right panel: Violin plots of select markers for the high-resolution leiden clusters 25

1 (resolution=0.4). Only the expression levels of infected cells are shown. Bottom panel: Violin plot of expression of Osr1 and Acta2, showing an overlap of a small Acta2+ 2 Osr1+ primary cells from E12.5 overlapping with the r2 cluster. (D) Alluvial diagrams 3 showing the inferred transition and growth/contraction of infected cells in 3D culture 4 from NonLFs to the Day 14 highlighted by the color of intermediate and final fate of 5 the four rLPC sub-clusters. PZL refers to Prdm16+Ztbt16+Lin28a (3-factor lentiviral 6 7 expression). PZLL refers to Prdm16+Ztbt16+Lin28a+Lin41(Trim71) (4-factor lentiviral expression). 8

9

## 10 Supplemental figure 15, Related to Figure 6

# High-resolution clustering of scRNA-seq cells for Waddington Optimal Transport (WOT) analysis

(A) Changes of mean expression levels of individual genes at a given time point
weighted by the probability of the final fate (rLPC or Transit) inferred by WOT. All
expression level in natural-log transformed UMI counts normalized by the total UMI
counts per cell. rLPC refers to reprogrammed limb progenitors. Transit refers to all
cells with the cluster annotation of (A1, A2, T1, T2, T3).

(B) Changes of mean expression levels of individual genes at a given time point
weighted by the probability of the final fate for individual rLPC fates (r1, r2, r3, E9). All
expression level in natural-log transformed UMI counts normalized by the total UMI
counts per cell. PZL refers to Prdm16+Ztbt16+Lin28a (3-factor lentiviral expression).
PZLL refers to Prdm16+Ztbt16+Lin28a+Lin41(Trim71) (4-factor lentiviral expression).
WPRE refers to Woodchuck Hepatitis Virus Posttranscriptional Response element,
representing lentiviral expression level.

#### 1 Supplemental figure 16

## Overexpression of PZL induces expression of LP marker genes in human adult fibroblasts

(A) Control (no transgene) virus- or PZL-infected human dermal fibroblasts (HDF) 4 were cultured on Matrigel in the presence of CFRSY for 18 days. (B, C) HDF, Control 5 and PZL-overexpressing cells were stained with SALL4 and LHX2 antibodies (B), or 6 7 NMYC and EGR1 antibodies (C). (D) After the PZL-expressing cells were cultured for 18 days, the cells were grafted into HH20 chicken FL buds, and then the grafted limbs 8 9 were harvested at HH32, 4 days after the manipulation. A few grafted PZL cells were integrated in cartilage and became Sox9 positive (a vellow arrowhead), whereas 10 control HDF do not differentiate into chondrocytes (n = 3 limbs each). Scale bars, 100 11 µm in (B), (C), (D). PZL refers to Prdm16+Ztbt16+Lin28a (3-factor lentiviral 12 expression). PZLL refers to Prdm16+Ztbt16+Lin28a+Lin41(Trim71) (4-factor lentiviral 13 expression). 14

15

#### 16 Supplemental figure 17

scRNA-Seg characterization of the human cells reprogrammed by PZL or PZLL 17 (A) UMAP plot of single cell transcriptome embedding of human cells infected with 18 empty, PZL-, PZLL- reprogramming factors and human dermal fibroblast (HDF) control. 19 20 (B) Violin plots of major markers for NonLFs, LPs in Matrigel cultured human cells with empty, PZL-, PZLL- reprogramming factors. (C) Combined UMAP embedding of 21 mouse and human single cell transcriptomes. The four panels highlight cells from 22 23 specified sample sources, with color contours representing the density of the corresponding sample source. PZL refers to Prdm16+Ztbt16+Lin28a (3-factor 24 lentiviral expression). PZLL refers to Prdm16+Ztbt16+Lin28a+Lin41(Trim71) (4-factor 25

1 lentiviral expression).

2

#### 3 Supplemental Table 1

#### 4 List of all scRNA-Seq libraries, Related to Figure 5

All inDrops and 10X v3 libraries used in the manuscript. The lower mapping rate for 5 the inDrop libraries stems from insufficient cleaning up of short primer-dimers in the 6 7 library. The numbers under quality control (QC) process represent the number of cellular barcodes for each library. "Initial CB" column represent the number of cellular 8 9 barcodes (CB) suggested by the 10X cellranger/dropEst pipeline. "After QC" column represent the remaining cellular barcode after cut-off of primarily mitochondrial content 10 and gene count per cell. "Relevant Cell type" column represent the remaining cellular 11 barcodes, after clustering and marker analysis for each library and removing irrelevant, 12 contaminating cell types, such as immune cells, muscle cells. "Singlet" column 13 represent the number of remaining cellular barcodes after putative doublets were 14 removed via Scrublet algorithm (Wolock et al. 2019). Prefix D means day after 15 infection and culture, prefix E means mouse embryonic time point post coitum, PZL 16 refers to Prdm16+Ztbt16+Lin28a (3-factor lentiviral expression). PZLL refers to 17 Prdm16+Ztbt16+Lin28a+Lin41(Trim71) (4-factor lentiviral expression). HA refers to 18 hyaluronan-based culture, F0 refers to Empty lentiviral infection control. NonLFs refers 19 20 to non-limb fibroblasts.

21

#### 22 Supplemental Table 2

Differentially expressed genes for clusters in resolution=0.2 and resolution=0.4
 (A) Differentially expressed genes contrasting each broad cluster (leiden cluster
 resolution=0.2) to NonLF cluster, results related to Fig. 5B

1 (B) Differentially expressed genes contrasting cells from reprogrammed limb progenitors (rLPCs) to 3D cultured limb progenitors (LPC), related to Fig. 5C. 2 (C) Differentially expressed genes contrasting cells from primary limb progenitor origin 3 in different culture condition (3D cultured primary vs Immediately harvested primary), 4 related to Fig. S13A 5 (D) Differentially expressed genes contrasting each fine cluster (leiden cluster 6 7 resolution=0.4) to NonLF cluster, adjusted p-value cut-off of 0.1, results related to Fig. S14C. 8 9 Column specifications: name1/name2 : The source that is compared to each other. There are three 10 distinct comparisons: PZL vs primary, PZLL vs primary, PZLL vs PZL. PZL 11 refers to Prdm16+Ztbt16+Lin28a (3-factor lentiviral expression). PZLL refers to 12 Prdm16+Ztbt16+Lin28a+Lin41(Trim71) (4-factor lentiviral expression). Primary 13 refers to primary limb progenitors cultured in 3D culture condition. 14 • feature : Gene symbol 15 pval : the p-value of the quasi-likelihood ratio test 16 adj pval : the adjusted p-values based on the pseudo bulk procedure 17 treating each captured library as distinct source, not the individual cells 18 • f statistic : the F-statistics 19 • df1 : the degrees of freedom of the test 20 • df2 : the degrees of freedom of the fit 21 • Ifc : the log2-fold change. 22 • For more specifics, refer to glmGamPoi package test de function. 23 24 Supplemental table 3 25

## 1 Differentially expressed genes for trajectories

(A) Weighted t-test results from PZL-infected as well as PZLL-infected cell trajectories 2 comparing successfully reprogrammed limb progenitor fate (rLPC) to transit fate 3 (Transit). Related to Fig. 6D, E, Fig. 15A 4 (B) Weighted t-test results from PZL-infected as well as PZLL-infected cell trajectories 5 comparing each r2 limb progenitor fate to the rLPC states closer to earlier limb 6 7 progenitors (r3/E9). Related to Fig. 15B 8 Column specifications: • All suffixes refer to the statistics for a particular dataset. PZL refers to 9 Prdm16+Ztbt16+Lin28a (3-factor lentiviral expression). PZLL refers to 10 Prdm16+Ztbt16+Lin28a+Lin41(Trim71) (4-factor lentiviral expression). 11 • Day : The time point after infection and 3D culture which cells are selected 12 to compare the trajectories. 13 14 name1/name2 : The clusters that are compared to. rLPC (r1/r2/r3/E9 clusters aggregated), Transit (A1/A2/T1/T2/T3 clusters aggregated). 15 • feature : Gene symbol 16 isTF: Whether the gene is a transcription factor, according to online 17 resource of AnimalTFDB (Zhang et al., 2012) 18 • fold change : Fold change between the two trajectories for the particular 19 20 dataset mean1/mean2 : weighted mean expression value based on the fate 21 22 probabilities of all cells. fraction expressed1/fraction expressed2 : weighted mean of the 23 occurrence of the particular gene in the group 24 t score : weighted t-test score 25

1	<ul> <li>t_pval : weighted t-test p-value</li> </ul>
2	<ul> <li>t_fdr : False Disvery Rate adjusting for the number of cells between groups</li> </ul>
3	
4	STAR Methods
5	Detailed methods are provided in the online version of this paper and include the
6	following:
7	• KEY RESOURCES TABLE
8	• LEAD CONTACT AND MATERIALS AVAILABILITY
9	• EXPERIMENTAL MODEL AND SUBJECT DETAILS
10	<ul> <li>Mouse and chicken embryos</li> </ul>
11	METHOD DETAILS
12	<ul> <li>Embryonic fibroblast isolation</li> </ul>
13	<ul> <li>Matrigel coating</li> </ul>
14	<ul> <li>Harvest and culture of limb progenitors</li> </ul>
15	<ul> <li>Quantitative PCR (qPCR)</li> </ul>
16	<ul> <li>Plasmid construction</li> </ul>
17	<ul> <li>Viral production</li> </ul>
18	<ul> <li>Reprogramming assay 1: Reprogramming for mouse embryonic non-limb</li> </ul>
19	fibroblasts using HA-hydrogels
20	<ul> <li>Reprogramming assay 2: Reprogramming for mouse embryonic non-limb</li> </ul>
21	fibroblasts using Matrigel
22	<ul> <li>Reprogramming assay 3: Reprogramming for human adult dermal</li> </ul>
23	fibroblasts using Matrigel
24	<ul> <li>Immunostaining</li> </ul>
25	<ul> <li>Micromass culture and Alcian blue staining</li> </ul>

1	<ul> <li>Probes and <i>in situ</i> hybridization</li> </ul>
2	<ul> <li>In ovo electroporation</li> </ul>
3	$\circ$ Tamoxifen and 4-Hydroxy Tamoxifen (4-OHT) treatment
4	<ul> <li>Cell transplantation to chicken embryos</li> </ul>
5	<ul> <li>RNA-Seq library preparation</li> </ul>
6	$\circ$ Dissociation and FAC-sorting of 3D cultured cells for single-cell RNA-Seq
7	(scRNA-seq)
8	<ul> <li>scRNA-seq library preparation: InDrops scRNA-seq</li> </ul>
9	<ul> <li>scRNA-seq library preparation: 10xGenomics scRNA-seq</li> </ul>
10	QUANTIFICATION AND STATISTICAL ANALYSIS
11	<ul> <li>RNA-Seq analyses</li> </ul>
12	○ scRNA-seq analyses
13	DATA AND CODE AVAILABILITY
14	
15	Supplemental Information

- 16 Supplemental information can be found online at xxxxxxxx.
- 17

## 18 STAR★METHODS

## 19 KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER		
Antibodies				
Chicken polyclonal anti-GFP	Abcam	ab13970; RRID: AB_300798		
Rabbit polyclonal anti-Lhx2	Millipore-Sigma	ABE1402;RRID:		
		AB_2722523		
Mouse monoclonal anti-Sall4	Abcam	ab57577; RRID: AB_2183366		
Rabbit polyclonal anti-Sox9	Millipore-Sigma	AB5535; RRID: AB_2239761		
Rabbit monoclonal anti-EGR1	Thermo Fisher	MA5-15009; RRID:		
	Scientific	AB_10982091		
Rabbit polyclonal anti-Collagen Type I	Rockland	600-401-103-0.1; RRID:		
		AB_2074625		
Mouse monoclonal anti-Nmyc	Santa Cruz	sc-53993; RRID: AB_831602		
	Biotechnology			

BiotechnologyMouse monoclonal anti-Msx1/2DSHB4G1. RRID: AB. 531788Mouse monoclonal anti-Meis1/2Santa Cruzsc.101850; RRID:BiotechnologyAB 2143143Rabbit polyclonal anti-phospho-HistoneMillipore-Sigma06-570; RRID: AB_310177H3 (pH3)Mouse monoclonal anti-Collagen TypeII-6B3; RRID: AB_528165Mouse monoclonal anti-MHCDSHBII-6B3; RRID: AB_2147781Mouse monoclonal anti-Human NucleiMillipore-SigmaMAB1281; RRID: AB_94090AntibodyChemicals and Recombinant ProteinsDSHBMF20; RRID: AB_94090DMEMgibco11995-0650PTI-MEMPolyethyleniminePolyScience23966-2EmbryoMax 0.1% Gelatin SolutionMilliporeES-006-8Trypin-EDTAgibco15240062FBSgibco16000044TypLE Expressgibco118882.Mercaptoethanolgibco118882.Mercaptoethanolgibco118882.Mercaptoethanolgibco118882.Mercaptoethanolgibco1180-050Chirigo21Tocris4423Fgf8bR&D Systems423-F8-025atRATocris4423Fgf8bCaryman ChemicalBIOMIMESYS, HA-scaffoldCELENYSN/A (Discontinued)NatrigelCorning354200TRIzolSigmaC2867-000MLBiocking ReagentRoche11096176001Target Retrieval SolutionDAKOS2369ULTRAhybinvitrogen <td< th=""><th>Mouse monocional anti-Ttap2c</th><th>Santa Cruz</th><th colspan="3">sc-12762; RRID: AB_667770</th></td<>	Mouse monocional anti-Ttap2c	Santa Cruz	sc-12762; RRID: AB_667770		
Mouse monoclonal anti-Msx1/2         DSHB         4G1; RRID: AB, 531788           Mouse monoclonal anti-Meis1/2         Santa Cruz         sc.101850; RRID:           Biotechnology         AB_2143143           Rabbit polyclonal anti-phospho-Histone         Milipore-Sigma         06-570; RRID: AB_310177           Mouse monoclonal anti-Collagen Type         DSHB         II-6B3; RRID: AB_2147781           Mouse monoclonal anti-Human Nuclei         Millipore-Sigma         MAB1281; RRID: AB_94090           Antibody         DSHB         II-6B3; RRID: AB_2147781           Mouse monoclonal anti-Human Nuclei         Millipore-Sigma         MAB1281; RRID: AB_94090           Antibody         gibco         11995-065         OPTI-MEM           OPTI-MEM         gibco         31985-062         Polysthylenimine           PolyScience         23966-2         EmbryoMax 0.1% Gelatin Solution         Millipore         ES-006-8           Trypsin-EDTA         Sigma-Aldrich         T3924         Pen Strep         gibco         16000044           TrypLE Express         gibco         12605-010         CELBANKER1         Amsbio         11888         22-4Mercaptoethanol         gibco         11985-023           MEM NEAA         gibco         11985-023         Gelatin Solution         Sigma-Addrich		Biotechnology	_		
Mouse monoclonal anti-Meis1/2Santa Cruzsc-101850; RRID: BiotechnologyAB_2143143Rabbit polyclonal anti-phospho-Histone H3 (pH3)Millipore-Sigma06-570; RRID: AB_310177Mouse monoclonal anti-Collagen Type IIDSHBII-6B3; RRID: AB_528165Mouse monoclonal anti-Human Nuclei AntibodyDSHBMF20; RRID: AB_2147781Mouse monoclonal anti-Human Nuclei AntibodyDSHBMF20; RRID: AB_94090Chemicals and Recombinant ProteinsMAB1281; RRID: AB_94090OPTI-MEMgibco31985-062PolyethyleinininePolyScience23966-2EmbryoMax 0. 1% Gelatin SolutionMilliporeES-006-BTrypsin-EDTASigma-AldrichT3924Pen Strepgibco16000044TrypLE Expressgibco16000044CELLBANKER1Amsbio118882-Mercaptoethanolgibco11440-050Chirs9021Tocris0485-023MEM NEAAgibco11440-050Chirs9021Tocris0423Y-27632Cayman Chemical10005583B431542Sigma-AldrichS34230TRIzolInvitrogen155960-026Insolution, 4-Hydroxy-TamoxifenSigmaT6648-13Corn oilSigmaC627-500MLBlocking ReagentRoche11096776001Target Retrieval SolutionDAKOS2369ULTRAhybinvitrogenAM8670NB/R/CIP TabletsRoche1103677001Vector LaboratoriesH1697471001Vector Laboratories <td>Mouse monoclonal anti-Msx1/2</td> <td>DSHB</td> <td>4G1; RRID: AB_531788</td>	Mouse monoclonal anti-Msx1/2	DSHB	4G1; RRID: AB_531788		
BiotechnologyAB_2143143Rabbit polyclonal anti-phospho-HistoneMillipore-Sigma06-570; RRID: AB_310177Mouse monoclonal anti-Collagen TypeDSHBII-6B3; RRID: AB_528165IIMuse monoclonal anti-MHCDSHBMF20; RRID: AB_2147781Mouse monoclonal anti-Human NucleiMillipore-SigmaMAE281; RRID: AB_2147781AntibodyMilliporeSigmaMB20; RRID: AB_2147781Chemicals and Recombinant Proteinsmouse monoclonal anti-Human NucleiMillipore-SigmaDMEMgibco11995-065OPTI-MEMDMEM 0.1% Gelatin SolutionMilliporeES-006-BTrypsin-EDTASigma-AldrichT3924Pen Strepgibco1800044TrypL Expressgibco12065-010CELBANKER1Amsbio118882-Mercaptoethanolgibco11140-050Chris9021Tocris4423Fg8bR&D Systems423-F8-025atRATocris06955SB431542Sigma-AldrichS3427-SMGY-27632Cayman Chemical10005683BIOMIMESYS, HA-scaffoldCELENYSN/A (Discontinued)MatrigelCorning354230TratoxifenSigmaT6648-1GCorn oilSigmaT6648-1GCorn oilSigmaT6648-1GCorn oilSigmaT6648-1GCorn oilSigmaT6648-1GCorn oilSigmaT6648-1GCorn oilSigmaT6648-1GCorn oilSigmaT6648-1G <t< td=""><td>Mouse monoclonal anti-Meis1/2</td><td>Santa Cruz</td><td>sc-101850; RRID:</td></t<>	Mouse monoclonal anti-Meis1/2	Santa Cruz	sc-101850; RRID:		
Rabbit polyclonal anti-phospho-Histone H3 (pH3)Millipore-Sigma06-570; RRID: AB_310177Mouse monoclonal anti-Collagen Type IIDSHBII-6B3; RRID: AB_528165Mouse monoclonal anti-HurDSHBMF20; RRID: AB_2147781Mouse monoclonal anti-HurDSHBMF20; RRID: AB_2147781Mouse monoclonal anti-Hurman NucleiMillipore-SigmaMAB1281; RRID: AB_94090AntibodyDEnemicals and Recombinant Proteins11995-065DMEMgibco31988-062PolyethyleniminePolyScience23966-2EmbryoMax 0.1% Gelatin SolutionMilliporeES-006-8Trypsin-EDTASigma-AldrichT3924Pen Strepgibco16000044TrypLE Expressgibco12605-010CELLBANKER1Amsbio118882-Mercaptoethanolgibco1140-050Chiri99021Tocris4423Fgf8bR&D Systems423-F8-025BIOMIMESYS, HA-scaffoldCELLENYSN/A (Discontinued)MatrigelCorning354230TRIZolInvitrogen155960-026Insolution, 4-Hydroxy-TamoxifenCalibochem5.08225.0001TamoxifenSigmaC6267.500MLBlocking ReagentRoche11096176001Target Retrieval SolutionDAKOS2369ULTRANybinvitrogenA5256NB7/BCIP TabletsRoche1103617001Vector LaboratoriesH1500Redin HDAPIRoche110362750DAKOSigmaA3157-25GFat Cor		Biotechnology	AB_2143143		
Mouse monoclonal anti-Collagen Type II         DSHB         II-6B3; RRID: AB_528165           Mouse monoclonal anti-Human Nuclei Antibody         Millipore-Sigma         MAB1281; RRID: AB_2147781           Mouse monoclonal anti-Human Nuclei Antibody         Millipore-Sigma         MAB1281; RRID: AB_94090           Chemicals and Recombinant Proteins         Millipore-Sigma         MAB1281; RRID: AB_94090           Chemicals and Recombinant Proteins         9jbco         31985-062           DMEM         gibco         31985-062           Polyethylenimine         PolyScience         23966-2           EmbryoMax 0.1% Gelatin Solution         Millipore         ES-006-B           Trypsin-EDTA         Sigma-Aldrich         T3924           Pen Strep         gibco         16000044           TypLE Express         gibco         18000024           CELLBANKER1         Amsbio         11888           2-Mercaptoethanol         gibco         21985-023           MEM NEAA         gibco         11440-050           Chri99021         Tocris         4423           Fgf8b         R&D Systems         423-F8-025           aIRA         Tocris         0695           SB431542         Sigma-Aldrich         S4317-SMG           Y-27632	Rabbit polyclonal anti-phospho-Histone H3 (pH3)	Millipore-Sigma	06-570; RRID: AB_310177		
Mouse monoclonal anti-HURCDSHBMF20; RRID: AB_2147781Mouse monoclonal anti-Human Nuclei AntibodyMillipore-SigmaMAB1281; RRID: AB_94090Chemicals and Recombinant Proteinsmouse monoclonal anti-Human NucleiMAB1281; RRID: AB_94090DMEMgibco31985-062OPTI-MEMgibco31985-062PolysthyleniminePolyScience23966-2EmbryoMax 0.1% Gelatin SolutionMilliporeES-006-BTrypsin-EDTASigma-AldrichT3924Pen Strepgibco15240062FBSgibco16000044TrypLE Expressgibco12605-010CELLBANKER1Amsbio118882-Mercaptoethanolgibco21985-023MEM NEAAgibco1140-050Chir39021Tooris4423Fgf8bR&D Systems423-F8-025atRATooris0695SB431542Sigma-AldrichS4317-5MGY-27632Cayman Chemical10005583BIOMIMESYS, HA-scaffoldCELENYSN/A (Discontinued)MatrigelCorning354230TRIzolInvitrogen155960-026InSolution, 4-Hydroxy-TamoxifenCalbiochem5.08225.0001TamoxifenSigmaC3267-500MLBlocking ReagentRoche1109176001Target Retrieval SolutionDAKOS2369ULTRAhybinvitrogenAM8670NBT/BCIP TabletsRoche11093163001DAPIRoche10236276001DRAQ5Thermo Scientific </td <td>Mouse monoclonal anti-Collagen Type</td> <td>DSHB</td> <td>II-6B3; RRID: AB_528165</td>	Mouse monoclonal anti-Collagen Type	DSHB	II-6B3; RRID: AB_528165		
Mouse monoclonal anti-Human Nuclei AntibodyMillipore-SigmaMAB1281; RRID: AB_94090AntibodyGhemicals and Recombinant ProteinsDMEMgibco11995-065OPTI-MEMgibco31985-062EmbryoMax 0.1% Gelatin SolutionMilliporeES-006-BTrypsin-EDTASigma-AldrichT3924Pen Strepgibco15240062FBSgibco16000044TrypLE Expressgibco12605-010CELLBANKER1Amsbio118882-Mercaptoethanolgibco21985-023MEM NEAAgibco11140-050Chrig9021Tooris4423Fgf8bR&D Systems423-F8-025atRATocris0695SB431542Sigma-AldrichS4317-5MGY-27632Cayman Chemical10005583BIOMIMESYS, HA-scaffoldCELENYSN/A (Discontinued)MatrigelCorning354230TRIzolInvitrogen15696-026Insolution, 4-Hydroxy-TamoxifenSigmaC8267-500MLBlocking ReagentRoche11096176001Target Retrieval SolutionDAKOS2369ULTRAhybInvitrogenAM8670DARJRacche110236276001DAROSigmaA3157-25GFast Green FCFSigmaA3157-25GTaranoxifenSigmaA3157-25GTarget Ritrier (100 µm)Falcon352360Cell strainer (100 µm)Falcon352360Cell strainer (100 µm)Falcon352360 <td>Mouse monoclonal anti-MHC</td> <td>DSHB</td> <td>MF20; RRID: AB_2147781</td>	Mouse monoclonal anti-MHC	DSHB	MF20; RRID: AB_2147781		
Antibody         gibco         11995-065           OPTI-MEM         gibco         31985-062           Polyethylenimine         PolyScience         23966-2           EmbryoMax 0.1% Gelatin Solution         Millipore         ES-006-B           Trypsin-EDTA         Sigma-Aldrich         T3924           Pen Strep         gibco         15240062           FBS         gibco         15240064           TrypLE Express         gibco         12605-010           CELLBANKER1         Amsbio         11888           2-Mercaptoethanol         gibco         1140-050           Chri9021         Tocris         4423           Fgf8b         R&D Systems         423-F8-025           atRA         Tocris         0695           SB431542         Sigma-Aldrich         S4317-5MG           Y-27632         Cayman Chemical         10005683           BIOMIMESYS, HA-scaffold         CELENYS         N/A (Discontinued)           Matrigel         Corning         354230           Trapes attribution         JAKO         S269-026           Insolution, 4-Hydroxy-Tamoxifen         Salibochem         5.08225.0001           Tamoxifen         Sigma         C2647-500ML	Mouse monoclonal anti-Human Nuclei	Millipore-Sigma	MAB1281; RRID: AB_94090		
Chemicals and Recombinant Proteins           DMEM         gibco         11995-065           OPTI-MEM         gibco         31985-062           Polyethylenimine         PolyScience         23966-2           EmbryoMax 0.1% Gelatin Solution         Millipore         ES-006-B           Trypsin-EDTA         Sigma-Aldrich         T3924           Pen Strep         gibco         15240062           FBS         gibco         16000044           TrypLE Express         gibco         12605-010           CELLBANKER1         Amsbio         11888           2-Mercaptoethanol         gibco         1140-050           Chir99021         Tocris         4423           Fgf8b         R&D Systems         423-F8-025           atRA         Tocris         0695           SB431542         Cayman Chemical         10005583           BIOMIMESYS, HA-scaffold         CELENYS         N/A (Discontinued)           Matrigel         Corning         354230           Insolution, 4-Hydroxy-Tamoxifen         Calbiochem         5.08225.0001           Tamoxifen         Sigma         C5646-16           Corn oil         Sigma         C5647-500ML           Blocking Reagent         Roc	Antibody				
DMEM         gibco         11995-065           OPTI-MEM         gibco         31985-062           Polyethylenimine         PolyScience         23966-2           EmbryoMax 0.1% Gelatin Solution         Millipore         ES-006-B           Trypsin-EDTA         Sigma-Aldrich         T3924           Pen Strep         gibco         16000044           TrypLE Express         gibco         12605-010           CELLBANKER1         Amsbio         11888           2-Mercaptoethanol         gibco         1140-050           Chir99021         Tocris         4423           Fg8b         R&D Systems         423-F8-025           atRA         Tocris         6095           SB431542         Sigma-Aldrich         S4317-5MG           Y-27632         Cayman Chemical         10005583           BIOMIMESYS, HA-scaffold         CELENYS         N/A (Discontinued)           Matrigel         Corring         354230           TRIzol         Invitrogen         155960-026           Insolution, 4-Hydroxy-Tamoxifen         Calbiocherm         5.08225.0001           Tamoxifen         Sigma         C8667-00ML           Blocking Reagent         Roche         11096176001 <tr< td=""><td>Chemicals and Recombinant Proteins</td><td></td><td></td></tr<>	Chemicals and Recombinant Proteins				
OPTI-MEM         gibco         31985-062           Polydethylenimine         PolyScience         23966-2           EmbryoMax 0.1% Gelatin Solution         Millipore         ES-006-B           Trypsin-EDTA         Sigma-Aldrich         T3924           Pen Strep         gibco         15240062           FBS         gibco         12605-010           CELLBANKER1         Amsbio         11888           2-Mercaptoethanol         gibco         114140-050           Chir99021         Tocris         4423           Fgf8b         R&D Systems         423-F8-025           atRA         Tocris         0695           SB431542         Sigma-Aldrich         S4317-5MG           Y-27632         Cayman Chemical         10005583           BIOMIMESYS, HA-scaffold         CELENYS         N/A (Discontinued)           Matrigel         Corning         354230           TRIzol         Invitrogen         155960-026           Insolution, 4-Hydroxy-Tamoxifen         Calbiochem         5.08225.0001           Tamoxifen         Sigma         C648-7500ML           Blocking Reagent         Roche         11096176001           Target Retrieval Solution         DAKO         S2360 <td>DMEM</td> <td>gibco</td> <td>11995-065</td>	DMEM	gibco	11995-065		
Polysthylenimine         PolyScience         23966-2           EmbryoMax 0.1% Gelatin Solution         Millipore         ES-006-B           Trypsin-EDTA         Sigma-Aldrich         T3924           Pen Strep         gibco         15240062           FBS         gibco         12605-010           CELLBANKER1         Amsbio         11888           2-Mercaptoethanol         gibco         11480-050           Chir99021         Tocris         4423           Fgf8b         R&D Systems         423-F8-025           atRA         Tocris         0695           SB431542         Sigma-Aldrich         S4317-5MG           Y-27632         Cayman Chemical         10005583           BIOMIMESYS, HA-scaffold         CELENYS         N/A (Discontinued)           Matrigel         Corning         354230           Traget Retrieval Solution         DAKO         S2369           ULTRAhyb         Invitrogen         45648-1G           Corn oil         Sigma         C8267-500ML           Blocking Reagent         Roche         11096176001           Target Retrieval Solution         DAKO         S2369           ULTRAhyb         Invitrogen         AM8670	OPTI-MEM	gibco	31985-062		
EmbryoMax 0.1% Gelatin Solution         Millipore         ES-006-B           Trypsin-EDTA         Sigma-Aldrich         T3924           Pen Strep         gibco         15240062           FBS         gibco         16000044           TrypLE Express         gibco         12605-010           CELLBANKER1         Amsbio         11888           2-Mercaptoethanol         gibco         11985-023           MEM NEAA         gibco         11140-050           Chir99021         Tocris         4423           Fgf8b         R&D Systems         423-F8-025           atRA         Tocris         0695           SB431542         Sigma-Aldrich         S4317-5MG           Y-27632         Cayman Chemical         10005583           BIOMIMESYS, HA-scaffold         CELENYS         N/A (Discontinued)           Matrigel         Corning         354230           TRIzol         Invitrogen         155960-026           InSolution, 4-Hydroxy-Tamoxifen         Calbiochem         5.08225.0001           Tamoxifen         Sigma         C8267-500ML           Blocking Reagent         Roche         11096176001           Target Retrieval Solution         DAKO         S2369 <t< td=""><td>Polyethylenimine</td><td>PolyScience</td><td>23966-2</td></t<>	Polyethylenimine	PolyScience	23966-2		
Trypsin-EDTA         Sigma-Aldrich         T3924           Pen Strep         gibco         15240062           FBS         gibco         16000044           TrypLE Express         gibco         12605-010           CELLBANKER1         Amsbio         11888           2-Mercaptoethanol         gibco         21985-023           MEM NEAA         gibco         11140-050           Chir99021         Tocris         4423           Fgf8b         R&D Systems         423-F8-025           atRA         Tocris         0695           SB431542         Sigma-Aldrich         S4317-5MG           Y-27632         Cayman Chemical         10005583           BIOMIMESYS, HA-scaffold         CELENYS         N/A (Discontinued)           Matrigel         Corning         354230           Trapcol         Invitrogen         155960-026           InSolution, 4-Hydroxy-Tamoxifen         Calbiochem         5.08225.0001           Tamoxifen         Sigma         C8647-500ML           Blocking Reagent         Roche         11096176001           Target Retrieval Solution         DAKO         S2369           ULTRAhyb         invitrogen         AM8670           NBT/BCIP	EmbryoMax 0.1% Gelatin Solution	Millipore	ES-006-B		
Pen Strep         gibco         15240062           FBS         gibco         16000044           TrypLE Express         gibco         12605-010           CELLBANKER1         Amsbio         11888           2-Mercaptoethanol         gibco         11888           2-Mercaptoethanol         gibco         11140-050           Chir99021         Tocris         4423           Fgf8b         R&D Systems         423-F8-025           atRA         Tocris         0695           SB431542         Sigma-Aldrich         S4317-5MG           Y-27632         Cayman Chemical         1000583           BIOMIMESYS, HA-scaffold         CELENYS         N/A (Discontinued)           Matrigel         Corning         354230           TRIzol         Invitrogen         155960-026           Insolution, 4-Hydroxy-Tamoxifen         Calbiochem         5.08225.0001           Tamoxifen         Sigma         C68267-500ML           Blocking Reagent         Roche         11096176001           Target Retrieval Solution         DAKO         S2369           ULTRAhyb         invitrogen         AM8670           NBT/BCIP Tablets         Roche         110236276001           DA	Trypsin-EDTA	Sigma-Aldrich	T3924		
FBS         gibco         16000044           TrypLE Express         gibco         12605-010           CELLBANKER1         Amsbio         11888           2-Mercaptoethanol         gibco         21985-023           MEM NEAA         gibco         11140-050           Chir99021         Tocris         4423           Fgf8b         R&D Systems         423-F8-025           atRA         Tocris         0695           SB431542         Sigma-Aldrich         S4317-5MG           Y-27632         Cayman Chemical         10005583           BIOMIMESYS, HA-scaffold         CELENYS         N/A (Discontinued)           Matrigel         Corning         354230           TRIzol         Invitrogen         155960-026           InSolution, 4-Hydroxy-Tamoxifen         Calbiochem         5.08225.0001           Tamoxifen         Sigma         T6648-16           Corn oil         Sigma         C8267-500ML           Blocking Reagent         Roche         11096176001           Target Retrieval Solution         DAKO         S2369           ULTRAhyb         invitrogen         AM8670           NBT/BCIP Tablets         Roche         110236276001           DAAQS <td>Pen Strep</td> <td>aibco</td> <td>15240062</td>	Pen Strep	aibco	15240062		
TrypLE Express         gibco         12605-010           CELLBANKER1         Amsbio         11888           2-Mercaptoethanol         gibco         21985-023           MEM NEAA         gibco         11140-050           Chir99021         Tocris         4423           Fgf8b         R&D Systems         423-F8-025           atRA         Tocris         0695           SB431542         Sigma-Aldrich         S4317-5MG           Y-27632         Cayman Chemical         10005583           BIOMIMESYS, HA-scaffold         CELENYS         N/A (Discontinued)           Matrigel         Corning         354230           TRIzol         Invitrogen         155960-026           InSolution, 4-Hydroxy-Tamoxifen         Calbiochem         5.08225.0001           Tamoxifen         Sigma         T5648-1G           Corn oil         Sigma         C8267-500ML           Blocking Reagent         Roche         11096176001           Target Retrieval Solution         DAKO         S2369           ULTRAhyb         invitrogen         AM8670           NBT/BCIP Tablets         Roche         11697471001           Vector Laboratories         H-1500           medium with DAPI<	FBS	gibco	16000044		
CELLBANKER1Amsbio118882-Mercaptoethanolgibco21985-023MEM NEAAgibco11140-050Chir99021Tocris4423Fgf8bR&D Systems423-F8-025atRATocris0695SB431542Sigma-AldrichS4317-5MGY-27632Cayman Chemical10005583BIOMIMESYS, HA-scaffoldCELENYSN/A (Discontinued)MatrigelCorning354230TRIzolInvitrogen155960-026InSolution, 4-Hydroxy-TamoxifenCalbiochem5.08225.0001TamoxifenSigmaC6867-500MLBlocking ReagentRoche11096176001Target Retrieval SolutionDAKOS2369ULTRAhybinvitrogenAM8670NBT/BCIP TabletsRoche11697471001Vector LaboratoriesH-1500medium with DAPICorning431220DAPIRoche10236276001DRAQ5Thermo Scientific62251SFCA syringe filter (0.45-µm)Corning431220Cell strainer (100 µm)Falcon35260Cell strainer (40 µm)VWR21008-949Alcian Blue 8GXSigmaA3157-25GFast Green FCFSigmaF7252T3 RNA polymeraseRoche11031163001PolybreneSigma-AldrichH9246-0-13-FDoxocyclineSigma-AldrichH9246-0-13-F	TrypLE Express	gibco	12605-010		
O-Based NumberProcession2-Mercaptoethanolgibco21985-023MEM NEAAgibco11140-050Chir99021Tocris4423Fgf8bR&D Systems423-F8-025atRATocris0695SB431542Sigma-AldrichS4317-5MGY-27632Cayman Chemical10005583BIOMIMESYS, HA-scaffoldCELENYSN/A (Discontinued)MatrigelCorning354230TRIzolInvitrogen155960-026InSolution, 4-Hydroxy-TamoxifenCalbiochem5.08225.0001TamoxifenSigmaC8267-500MLBlocking ReagentRoche11096176001Target Retrieval SolutionDAKOS2369ULTRAhybinvitrogenAM8670NBT/BCIP TabletsRoche11697471001Vector LaboratoriesH-1500DAPIRoche10236276001DRAQ5Thermo Scientific62251SFCA syringe filter (0.45-µm)Corning431220Cell strainer (100 µm)Falcon352360Cell strainer (40 µm)VWR2108-949Alcian Blue 8GXSigmaA3157-25GFast Green FCFSigmaF7252T3 RNA polymeraseRoche11031163001PolybreneSigma-AldrichH9268-10GGlass Bottom Multi-well Plate, 24-wellMatTek orporationP24G-0-13-FDoxocyclineSigma-AldrichH9268-10G	CELLBANKER1	Amshio	11888		
Distribution         giboo         1140-050           MEM NEAA         gibco         11140-050           Chir99021         Tocris         4423           Fgf8b         R&D Systems         423-F8-025           atRA         Tocris         0695           SB431542         Sigma-Aldrich         S4317-5MG           Y-27632         Cayman Chemical         10005583           BIOMIMESYS, HA-scaffold         CELENYS         N/A (Discontinued)           Matrigel         Corning         354230           TRIzol         Invitrogen         155960-026           Insolution, 4-Hydroxy-Tamoxifen         Calbiochem         5.08225.0001           Tamoxifen         Sigma         C8267-500ML           Blocking Reagent         Roche         11096176001           Target Retrieval Solution         DAKO         S2369           ULTRAhyb         invitrogen         AM8670           NBT/BCIP Tablets         Roche         11697471001           Vectashield hardset antifade mounting medium with DAPI         Vector Laboratories         H-1500           DAPI         Roche         10236276001         DRAQ5           Strainer (40 µm)         Falcon         352360           Cell strainer (100 µm) <td>2-Mercaptoethanol</td> <td>aibco</td> <td>21985-023</td>	2-Mercaptoethanol	aibco	21985-023		
Internation         gibbo         Intro order           Chir99021         Tocris         4423           Fgf8b         R&D Systems         423-F8-025           atRA         Tocris         0695           SB431542         Sigma-Aldrich         S4317-5MG           Y-27632         Cayman Chemical         10005583           BIOMIMESYS, HA-scaffold         CELENYS         N/A (Discontinued)           Matrigel         Corning         354230           TRIzol         Invitrogen         155960-026           InSolution, 4-Hydroxy-Tamoxifen         Calbiochem         5.08225.0001           Tamoxifen         Sigma         T5648-1G           Corn oil         Sigma         C8267-500ML           Blocking Reagent         Roche         11096176001           Target Retrieval Solution         DAKO         S2369           ULTRAhyb         invitrogen         AM8670           NBT/BCIP Tablets         Roche         11697471001           Vector Laboratories         H-1500           medium with DAPI         Poter         Laboratories           DAPI         Roche         10236276001           DRAQ5         Thermo Scientific         62251           SCA syringe f	MEM NEAA	gibco	11140-050		
SimotochR&D Systems423-F8-025atRATocris0695SB431542Sigma-AldrichS4317-5MGY-27632Cayman Chemical10005583BIOMIMESYS, HA-scaffoldCELENYSN/A (Discontinued)MatrigelCorning354230TRIzolInvitrogen155960-026InSolution, 4-Hydroxy-TamoxifenCalbiochem5.08225.0001TamoxifenSigmaT5648-1GCorn oilSigmaC8267-500MLBlocking ReagentRoche11096176001Target Retrieval SolutionDAKOS2369ULTRAhybinvitrogenAM8670NBT/BCIP TabletsRoche11697471001Vectashield hardset antifade mounting medium with DAPIVector LaboratoriesH-1500H-1500DAPIRoche10236276001DRAQ5Thermo Scientific62251SFCA syringe filter (0.45-µm)Corning431220Cell strainer (100 µm)Falcon352360Cell strainer (40 µm)VWR21008-949Alcian Blue 8GXSigmaA3157-25GFast Green FCFSigmaF7252T3 RNA polymeraseRoche11031163001PolybreneSigma-AldrichH9268-10GGlass Bottom Multi-well Plate, 24-wellMatTek orporationP24G-0-13-FDoxycyclineSigma-AldrichD3447-500MG	Chir99021	Tocris	4423		
InduPartPartatRATooris0695SB431542Sigma-AldrichS4317-5MGY-27632Cayman Chemical10005583BIOMIMESYS, HA-scaffoldCELENYSN/A (Discontinued)MatrigelCorning354230TRIzolInvitrogen155960-026Insolution, 4-Hydroxy-TamoxifenCalbiochem5.08225.0001TamoxifenSigmaT5648-1GCorn oilSigmaC8267-500MLBlocking ReagentRoche11096176001Target Retrieval SolutionDAKOS2369ULTRAhybinvitrogenAM8670NBT/BCIP TabletsRoche11697471001Vector LaboratoriesH-1500medium with DAPIRoche10236276001DRAQ5Thermo Scientific62251SFCA syringe filter (0.45-µm)Corning431220Cell strainer (100 µm)Falcon352360Cell strainer (40 µm)VWR21008-949Alcian Blue 8GXSigmaA3157-25GFast Green FCFSigmaF7252T3 RNA polymeraseRoche11031163001PolybreneSigma-AldrichH9268-10GGlass Bottom Multi-well Plate, 24-wellMatTek orporationP24G-0-13-FDoxycyclineSigma-AldrichD3447-500MG	Faf8h	R&D Systems	423-F8-025		
BartTourisTourisTourisSB431542Sigma-AldrichS4317-5MGY-27632Cayman Chemical10005583BIOMIMESYS, HA-scaffoldCELENYSN/A (Discontinued)MatrigelCorning354230TRIzolInvitrogen155960-026InSolution, 4-Hydroxy-TamoxifenCalbiochem5.08225.0001TamoxifenSigmaC8267-500MLBlocking ReagentRoche11096176001Target Retrieval SolutionDAKOS2369ULTRAhybinvitrogenAM8670NBT/BCIP TabletsRoche11697471001Vectashield hardset antifade mounting medium with DAPIVector LaboratoriesDAPIRoche10236276001DRAQ5Thermo Scientific62251SFCA syringe filter (0.45-µm)Corning431220Cell strainer (100 µm)Falcon352360Cell strainer (40 µm)VWR21008-949Alcian Blue 8GXSigmaA3157-25GFast Green FCFSigmaF7252T3 RNA polymeraseRoche11031163001PolybreneSigma-AldrichH9268-10GGlass Bottom Multi-well Plate, 24-wellMatTek orporationP24G-0-13-FDoxycyclineSigma-AldrichD3447-500MG	atRA	Tocris	0695		
BUD 1942Dignm AuthonDignm AuthonY-27632Cayman Chemical10005583BIOMIMESYS, HA-scaffoldCELENYSN/A (Discontinued)MatrigelCorning354230TRIzolInvitrogen155960-026InSolution, 4-Hydroxy-TamoxifenCalbiochem5.08225.0001TamoxifenSigmaT5648-1GCorn oilSigmaC8267-500MLBlocking ReagentRoche11096176001Target Retrieval SolutionDAKOS2369ULTRAhybinvitrogenAM8670NBT/BCIP TabletsRoche11697471001Vectashield hardset antifade mounting medium with DAPIVector LaboratoriesDAPIRoche10236276001DRAQ5Thermo Scientific62251SFCA syringe filter (0.45-µm)Corning431220Cell strainer (100 µm)Falcon352360Cell strainer (40 µm)VWR21008-949Alcian Blue 8GXSigmaA3157-25GFast Green FCFSigmaF7252T3 RNA polymeraseRoche11031163001PolybreneSigma-AldrichH9268-10GGlass Bottom Multi-well Plate, 24-wellMatTek orporationP24G-0.13-FDoxycyclineSigma-AldrichH9268-10G	SB431542	Sigma-Aldrich	\$4317-5MG		
TransloadDayman one numberBIOMIMESYS, HA-scaffoldCELENYSMatrigelCorningTRIzolInvitrogenInSolution, 4-Hydroxy-TamoxifenCalbiochemSigmaT5648-1GCorn oilSigmaBlocking ReagentRocheInsolution, 4-Hydroxy-TamoxifenCalbiochemTamoxifenSigmaCorn oilSigmaBlocking ReagentRoche11096176001Target Retrieval SolutionDAKOVectashield hardset antifade mountingmedium with DAPIDAPIRocheDAPIRocheDAQ5Thermo ScientificSFCA syringe filter (0.45-µm)Cell strainer (100 µm)Falcon352360Cell strainer (40 µm)Alcian Blue 8GXSigmaFals Green FCFSigmaFast Bottom Multi-well Plate, 24-wellMatTek orporationP24G-0-13-FDoxycyclineSigma-AldrichH9268-10GG	V-27632	Cayman Chemical	10005583		
Distribute Do, HArssendidDELEVINGHArssendidMatrigelCorning354230TRIzolInvitrogen155960-026InSolution, 4-Hydroxy-TamoxifenCalbiochem5.08225.0001TamoxifenSigmaT5648-1GCorn oilSigmaC8267-500MLBlocking ReagentRoche11096176001Target Retrieval SolutionDAKOS2369ULTRAhybinvitrogenAM8670NBT/BCIP TabletsRoche11697471001Vectashield hardset antifade mounting medium with DAPIVector LaboratoriesH-1500H-1500DAPIRoche10236276001DRAQ5Thermo Scientific62251SFCA syringe filter (0.45-µm)Corning431220Cell strainer (100 µm)Falcon352360Cell strainer (40 µm)VWR21008-949Alcian Blue 8GXSigmaA3157-25GFast Green FCFSigmaF7252T3 RNA polymeraseRoche11031163001PolybreneSigma-AldrichH9268-10GGlass Bottom Multi-well Plate, 24-wellMatTek orporationP24G-0-13-FDoxveryelineSigma-AldrichD3447-500MG	BIOMIMESYS HA-scaffold		N/A (Discontinued)		
MangerSoftmingSoftageTRIzolInvitrogen155960-026InSolution, 4-Hydroxy-TamoxifenCalbiochem5.08225.0001TamoxifenSigmaT5648-1GCorn oilSigmaC8267-500MLBlocking ReagentRoche11096176001Target Retrieval SolutionDAKOS2369ULTRAhybinvitrogenAM8670NBT/BCIP TabletsRoche11697471001Vectashield hardset antifade mounting medium with DAPIVector LaboratoriesDAPIRoche10236276001DRAQ5Thermo ScientificSFCA syringe filter (0.45-µm)Corning431220Cell strainer (100 µm)Falcon352360Cell strainer (40 µm)VWRAlcian Blue 8GXSigmaA3157-25GSigmaFast Green FCFSigmaFast Green FCFSigmaGlass Bottom Multi-well Plate, 24-wellMatTek orporationPolybreneSigma-AldrichDoxycyclineSigma-AldrichDoxycyclineSigma-AldrichDoxycyclineSigma-AldrichDoxycyclineSigma-Aldrich	Matricel	Corning	354230		
Introgen1030020InSolution, 4-Hydroxy-TamoxifenCalbiochem5.08225.0001TamoxifenSigmaT5648-1GCorn oilSigmaC8267-500MLBlocking ReagentRoche11096176001Target Retrieval SolutionDAKOS2369ULTRAhybinvitrogenAM8670NBT/BCIP TabletsRoche11697471001Vectashield hardset antifade mounting medium with DAPIVector LaboratoriesDAPIRoche10236276001DRAQ5Thermo Scientific62251SFCA syringe filter (0.45-μm)Corning431220Cell strainer (100 μm)Falcon352360Cell strainer (40 μm)VWR21008-949Alcian Blue 8GXSigmaA3157-25GFast Green FCFSigmaF7252T3 RNA polymeraseRoche11031163001PolybreneSigma-AldrichH9268-10GGlass Bottom Multi-well Plate, 24-wellMatTek orporationP24G-0-13-FDoxvcyclineSigma-AldrichD3447-500MG	TRIzol	Invitrogen	155960-026		
Insolution, 4-Frydroxy famolationCatablechem5.00225.0001TamoxifenSigmaT5648-1GCorn oilSigmaC8267-500MLBlocking ReagentRoche11096176001Target Retrieval SolutionDAKOS2369ULTRAhybinvitrogenAM8670NBT/BCIP TabletsRoche11697471001Vectashield hardset antifade mounting medium with DAPIVector LaboratoriesDAPIRoche10236276001DRAQ5Thermo Scientific62251SFCA syringe filter (0.45-μm)Corning431220Cell strainer (100 μm)Falcon352360Cell strainer (40 μm)VWR21008-949Alcian Blue 8GXSigmaA3157-25GFast Green FCFSigmaF7252T3 RNA polymeraseRoche11031163001PolybreneSigma-AldrichH9268-10GGlass Bottom Multi-well Plate, 24-wellMatTek orporationP24G-0-13-FDoxvcyclineSigma-AldrichD3447-500MG	InSolution 1-Hydroxy-Tamovifen	Calbiochem	5 08225 0001		
TantoviterinSigma13040-10Corn oilSigmaC8267-500MLBlocking ReagentRoche11096176001Target Retrieval SolutionDAKOS2369ULTRAhybinvitrogenAM8670NBT/BCIP TabletsRoche11697471001Vectashield hardset antifade mounting medium with DAPIVector LaboratoriesDAPIRoche10236276001DRAQ5Thermo Scientific62251SFCA syringe filter (0.45-µm)Corning431220Cell strainer (100 µm)Falcon352360Cell strainer (40 µm)VWR21008-949Alcian Blue 8GXSigmaA3157-25GFast Green FCFSigmaF7252T3 RNA polymeraseRoche11031163001PolybreneSigma-AldrichH9268-10GGlass Bottom Multi-well Plate, 24-wellMatTek orporationP24G-0-13-FDoxycyclineSigma-AldrichD3447-500MG	Tamovifen	Sigma	T56/8-1C		
Blocking ReagentRoche11096176001Target Retrieval SolutionDAKO\$2369ULTRAhybinvitrogenAM8670NBT/BCIP TabletsRoche11697471001Vectashield hardset antifade mounting medium with DAPIVector LaboratoriesDAPIRoche10236276001DRAQ5Thermo Scientific62251SFCA syringe filter (0.45-µm)Corning431220Cell strainer (100 µm)Falcon352360Cell strainer (40 µm)VWR21008-949Alcian Blue 8GXSigmaA3157-25GFast Green FCFSigmaF7252T3 RNA polymeraseRoche11031163001PolybreneSigma-AldrichH9268-10GGlass Bottom Multi-well Plate, 24-wellMatTek orporationP24G-0-13-FDoxvcyclineSigma-AldrichD3447-500MG		Sigma	C8267-500MI		
Diocking ReagentRoche11030170001Target Retrieval SolutionDAKO\$2369ULTRAhybinvitrogenAM8670NBT/BCIP TabletsRoche11697471001Vectashield hardset antifade mounting medium with DAPIVector LaboratoriesDAPIRoche10236276001DRAQ5Thermo Scientific62251SFCA syringe filter (0.45-µm)Corning431220Cell strainer (100 µm)Falcon352360Cell strainer (40 µm)VWR21008-949Alcian Blue 8GXSigmaA3157-25GFast Green FCFSigmaF7252T3 RNA polymeraseRoche11031163001PolybreneSigma-AldrichH9268-10GGlass Bottom Multi-well Plate, 24-wellMatTek orporationP24G-0-13-FDoxvcyclineSigma-AldrichD3447-500MG	Blocking Reagont	Docho	11096176001		
Target Refleval SolutionDARO32309ULTRAhybinvitrogenAM8670NBT/BCIP TabletsRoche11697471001Vectashield hardset antifade mounting medium with DAPIVector LaboratoriesH-1500DAPIRoche10236276001DRAQ5Thermo Scientific62251SFCA syringe filter (0.45-µm)Corning431220Cell strainer (100 µm)Falcon352360Cell strainer (40 µm)VWR21008-949Alcian Blue 8GXSigmaA3157-25GFast Green FCFSigmaF7252T3 RNA polymeraseRoche11031163001PolybreneSigma-AldrichH9268-10GGlass Bottom Multi-well Plate, 24-wellMatTek orporationP24G-0-13-FDoxvcvclineSigma-AldrichD3447-500MG	Diocking Reagent	TOCHE	11030170001		
NBT/BCIP TabletsRoche11697471001Vectashield hardset antifade mounting medium with DAPIVector LaboratoriesH-1500DAPIRoche10236276001DRAQ5Thermo Scientific62251SFCA syringe filter (0.45-μm)Corning431220Cell strainer (100 μm)Falcon352360Cell strainer (40 μm)VWR21008-949Alcian Blue 8GXSigmaA3157-25GFast Green FCFSigmaF7252T3 RNA polymeraseRoche11031163001PolybreneSigma-AldrichH9268-10GGlass Bottom Multi-well Plate, 24-wellMatTek orporationP24G-0-13-FDoxvcyclineSigma-AldrichD3447-500MG	Target Petricul Solution		60360		
NB1/BCIP TabletsRoche11097471001Vectashield hardset antifade mounting medium with DAPIVector LaboratoriesH-1500DAPIRoche10236276001DRAQ5Thermo Scientific62251SFCA syringe filter (0.45-µm)Corning431220Cell strainer (100 µm)Falcon352360Cell strainer (40 µm)VWR21008-949Alcian Blue 8GXSigmaA3157-25GFast Green FCFSigmaF7252T3 RNA polymeraseRoche11031163001PolybreneSigma-AldrichH9268-10GGlass Bottom Multi-well Plate, 24-wellMatTek orporationP24G-0-13-FDoxycyclineSigma-AldrichD3447-500MG	Target Retrieval Solution	DAKO	S2369		
Vector LaboratoriesH-1500medium with DAPIRoche10236276001DAPIRoche10236276001DRAQ5Thermo Scientific62251SFCA syringe filter (0.45-μm)Corning431220Cell strainer (100 μm)Falcon352360Cell strainer (40 μm)VWR21008-949Alcian Blue 8GXSigmaA3157-25GFast Green FCFSigmaF7252T3 RNA polymeraseRoche11031163001PolybreneSigma-AldrichH9268-10GGlass Bottom Multi-well Plate, 24-wellMatTek orporationP24G-0-13-FDoxycyclineSigma-AldrichD3447-500MG	Target Retrieval Solution ULTRAhyb	DAKO invitrogen	S2369 AM8670		
DAPIRoche10236276001DRAQ5Thermo Scientific62251SFCA syringe filter (0.45-μm)Corning431220Cell strainer (100 μm)Falcon352360Cell strainer (40 μm)VWR21008-949Alcian Blue 8GXSigmaA3157-25GFast Green FCFSigmaF7252T3 RNA polymeraseRoche11031163001PolybreneSigma-AldrichH9268-10GGlass Bottom Multi-well Plate, 24-wellMatTek orporationP24G-0-13-FDoxycyclineSigma-AldrichD3447-500MG	Target Retrieval Solution ULTRAhyb NBT/BCIP Tablets	DAKO invitrogen Roche	S2369 AM8670 11697471001		
DRAQ5Thermo Scientific62251SFCA syringe filter (0.45-μm)Corning431220Cell strainer (100 μm)Falcon352360Cell strainer (40 μm)VWR21008-949Alcian Blue 8GXSigmaA3157-25GFast Green FCFSigmaF7252T3 RNA polymeraseRoche11031163001PolybreneSigma-AldrichH9268-10GGlass Bottom Multi-well Plate, 24-wellMatTek orporationP24G-0-13-FDoxycyclineSigma-AldrichD3447-500MG	Target Retrieval Solution ULTRAhyb NBT/BCIP Tablets Vectashield hardset antifade mounting medium with DAPI	DAKO invitrogen Roche Vector Laboratories	S2369 AM8670 11697471001 H-1500		
SFCA syringe filter (0.45-μm)Corning431220Cell strainer (100 μm)Falcon352360Cell strainer (40 μm)VWR21008-949Alcian Blue 8GXSigmaA3157-25GFast Green FCFSigmaF7252T3 RNA polymeraseRoche11031163001PolybreneSigma-AldrichH9268-10GGlass Bottom Multi-well Plate, 24-wellMatTek orporationP24G-0-13-FDoxycyclineSigma-AldrichD3447-500MG	Target Retrieval Solution ULTRAhyb NBT/BCIP Tablets Vectashield hardset antifade mounting medium with DAPI DAPI	DAKO invitrogen Roche Vector Laboratories Roche	S2369 AM8670 11697471001 H-1500 10236276001		
Cell strainer (100 μm)Falcon352360Cell strainer (40 μm)VWR21008-949Alcian Blue 8GXSigmaA3157-25GFast Green FCFSigmaF7252T3 RNA polymeraseRoche11031163001PolybreneSigma-AldrichH9268-10GGlass Bottom Multi-well Plate, 24-wellMatTek orporationP24G-0-13-FDoxycyclineSigma-AldrichD3447-500MG	Target Retrieval Solution ULTRAhyb NBT/BCIP Tablets Vectashield hardset antifade mounting medium with DAPI DAPI DRAQ5	DAKO invitrogen Roche Vector Laboratories Roche Thermo Scientific	S2369 AM8670 11697471001 H-1500 10236276001 62251		
Cell strainer (40 µm)VWR21008-949Alcian Blue 8GXSigmaA3157-25GFast Green FCFSigmaF7252T3 RNA polymeraseRoche11031163001PolybreneSigma-AldrichH9268-10GGlass Bottom Multi-well Plate, 24-wellMatTek orporationP24G-0-13-FDoxycyclineSigma-AldrichD3447-500MG	Target Retrieval Solution ULTRAhyb NBT/BCIP Tablets Vectashield hardset antifade mounting medium with DAPI DAPI DRAQ5 SFCA syringe filter (0.45-um)	DAKO invitrogen Roche Vector Laboratories Roche Thermo Scientific Corning	S2369 AM8670 11697471001 H-1500 10236276001 62251 431220		
Alcian Blue 8GXSigmaA3157-25GFast Green FCFSigmaF7252T3 RNA polymeraseRoche11031163001PolybreneSigma-AldrichH9268-10GGlass Bottom Multi-well Plate, 24-wellMatTek orporationP24G-0-13-FDoxycyclineSigma-AldrichD3447-500MG	Target Retrieval Solution ULTRAhyb NBT/BCIP Tablets Vectashield hardset antifade mounting medium with DAPI DAPI DRAQ5 SFCA syringe filter (0.45-µm) Cell strainer (100 µm)	DAKO invitrogen Roche Vector Laboratories Roche Thermo Scientific Corning Falcon	S2369 AM8670 11697471001 H-1500 10236276001 62251 431220 352360		
Fast Green FCFSigmaF7252T3 RNA polymeraseRoche11031163001PolybreneSigma-AldrichH9268-10GGlass Bottom Multi-well Plate, 24-wellMatTek orporationP24G-0-13-FDoxycyclineSigma-AldrichD3447-500MG	Target Retrieval Solution ULTRAhyb NBT/BCIP Tablets Vectashield hardset antifade mounting medium with DAPI DAPI DRAQ5 SFCA syringe filter (0.45-µm) Cell strainer (100 µm) Cell strainer (40 µm)	DAKO invitrogen Roche Vector Laboratories Roche Thermo Scientific Corning Falcon VWR	S2369 AM8670 11697471001 H-1500 10236276001 62251 431220 352360 21008-949		
T3 RNA polymeraseRoche11031163001PolybreneSigma-AldrichH9268-10GGlass Bottom Multi-well Plate, 24-wellMatTek orporationP24G-0-13-FDoxycyclineSigma-AldrichD3447-500MG	Target Retrieval SolutionULTRAhybNBT/BCIP TabletsVectashield hardset antifade mounting medium with DAPIDAPIDRAQ5SFCA syringe filter (0.45-μm)Cell strainer (100 μm)Cell strainer (40 μm)Alcian Blue 8GX	DAKO invitrogen Roche Vector Laboratories Roche Thermo Scientific Corning Falcon VWR Sigma	S2369 AM8670 11697471001 H-1500 10236276001 62251 431220 352360 21008-949 A3157-25G		
PolybreneSigma-AldrichH9268-10GGlass Bottom Multi-well Plate, 24-wellMatTek orporationP24G-0-13-FDoxycyclineSigma-AldrichD3447-500MG	Target Retrieval SolutionULTRAhybNBT/BCIP TabletsVectashield hardset antifade mounting medium with DAPIDAPIDRAQ5SFCA syringe filter (0.45-μm)Cell strainer (100 μm)Cell strainer (40 μm)Alcian Blue 8GXFast Green FCF	DAKO invitrogen Roche Vector Laboratories Roche Thermo Scientific Corning Falcon VWR Sigma Sigma	S2369 AM8670 11697471001 H-1500 10236276001 62251 431220 352360 21008-949 A3157-25G F7252		
Glass Bottom Multi-well Plate, 24-well     MatTek orporation     P24G-0-13-F       Doxycycline     Sigma-Aldrich     D3447-500MG	Target Retrieval SolutionULTRAhybNBT/BCIP TabletsVectashield hardset antifade mounting medium with DAPIDAPIDRAQ5SFCA syringe filter (0.45-μm)Cell strainer (100 μm)Cell strainer (40 μm)Alcian Blue 8GXFast Green FCFT3 RNA polymerase	DAKO invitrogen Roche Vector Laboratories Roche Thermo Scientific Corning Falcon VWR Sigma Sigma Roche	S2369 AM8670 11697471001 H-1500 10236276001 62251 431220 352360 21008-949 A3157-25G F7252 11031163001		
Doxycycline Siama-Aldrich D3447-500MG	Target Retrieval SolutionULTRAhybNBT/BCIP TabletsVectashield hardset antifade mounting medium with DAPIDAPIDRAQ5SFCA syringe filter (0.45-μm)Cell strainer (100 μm)Cell strainer (40 μm)Alcian Blue 8GXFast Green FCFT3 RNA polymerasePolvbrene	DAKO invitrogen Roche Vector Laboratories Roche Thermo Scientific Corning Falcon VWR Sigma Sigma Roche Sigma-Aldrich	S2369 AM8670 11697471001 H-1500 10236276001 62251 431220 352360 21008-949 A3157-25G F7252 11031163001 H9268-10G		
	Target Retrieval Solution ULTRAhyb NBT/BCIP Tablets Vectashield hardset antifade mounting medium with DAPI DAPI DRAQ5 SFCA syringe filter (0.45-µm) Cell strainer (100 µm) Cell strainer (40 µm) Alcian Blue 8GX Fast Green FCF T3 RNA polymerase Polybrene Glass Bottom Multi-well Plate, 24-well	DAKO invitrogen Roche Vector Laboratories Roche Thermo Scientific Corning Falcon VWR Sigma Sigma Sigma Sigma Roche Sigma-Aldrich MatTek orporation	S2369 AM8670 11697471001 H-1500 10236276001 62251 431220 352360 21008-949 A3157-25G F7252 11031163001 H9268-10G P24G-0-13-F		

Critical Commercial Assays					
RNeasy Mini Kit	Qiagen	74104			
SuperScript III First-Strand Synthesis	Thermo Fisher	18080-051			
System					
Brilliant III Ultra-Fast SYBR Green	Agilent	600882			
QPCR Master Mix	technologies				
DIG RNA Labeling Mix	Roche	11277073910			
Gateway BP Clonase II Enzyme mix	Invitrogen	11789-020			
Gateway LR Clonase II Enzyme mix	Invitrogen	11791-020			
Gibson Assembly Master Mix	New England Biolabs	E2611S			
10x Genomics Chromium Single Cell 3' Reagent Kit (v.3 Chemistry)	10x Genomics	1000092			
Deposited Data					
Experimental Models: Cell Lines					
Plat-F	Morita et al 2000	N/A			
HEK293T		CRI-3216			
Human Dermal Eibroblasts-adult	iXColle				
	Biotechnologies	10110-014			
Experimental Models: Organisms/Stra	nins				
White leghorn chicken eggs	Charles River	N/A			
GEP chicken eggs	Clemson Univ	Chanman et al. 2005			
Prv1-CreER-IRES-GEP mouse	Case Western	Kawanami et al. 2009			
	Reserve Univ.	Rawanann et al., 2003			
Ai9 mouse (Gt[ROSA]26Sor <sup>tm9[CAG-</sup>	The Jackson	Stock no. 007909			
tdTomato]Hze)	Laboratory				
CAG-GFP mouse (C57BL/6-Tg [CAG-	The Jackson	Stock no. 003291			
EGFP] <sup>10sb/J</sup> )	Laboratory				
CD1	Charles River	Strain code: 022			
Oligonucleotides					
Sequences of primers for qPCR and		N/A			
RNA probes, see Supplemental Table 4					
Recombinant DNA					
pT2A-CAGGS-H2BmCherry-IRES-	This paper	N/A			
ZsGreen1					
pT2A-CAGGS-EGR1-IRES-ZsGreen1	This paper	N/A			
pMXs-gw	Addgene	#18656			
pMXs-EGR1	Addgene	#52724			
pMXs-Prx1	This paper	N/A			
pMXs-Nmyc	Addgene	#50772			
pMXs-Pbx2	This paper	N/A			
pMXs-Jarid2	This paper	N/A			
pMXs-Sall1	This paper	N/A			
pMXs-Hand2	This paper	N/A			
pMXs-Msx1	This paper	N/A			
pMXs-Ldb2	This paper	N/A			
pMXs-1bx5	This paper	N/A			
pMXs-Meis1	Addgene	#131605			
pMXs-Ishz2	This paper	N/A			
pMXs-Hoxd10	This paper	N/A			
pMXS-ZBTB16	This paper	N/A			

pMXs-Lhx2	This paper	N/A
pMXs-Prdm16	This paper	N/A
pMXs-Etv4	This paper	N/A
pMXs-Tfap2a	This paper	N/A
pMXs-Lin28a	Addgene	#47902
pMXs-Lin41	Addgene	#52716
pLV-mCherry	Addgene	#36084
FUW-TetO-MCS	Addgene	#84008
FUW-M2rtTA	Addgene	#20342
FUW-TetO-PLZF	Addgene	#61543
FUW-TetO-Prdm16	This study	N/A
FUW-TetO-Lin28a	Addgene	#60345
FUW-TetO-Lin41	This study	N/A
pCMV-VSV-G	Addgene	#8454
psPAX2	Addgene	#12260
pBS-cSall4-probe	This study	N/A
pBS-cLin28a-probe	This study	N/A
pBS-cLin41-probe	This study	N/A
pBS-cEgr1-probe	This study	N/A
Software and Algorithms		l
ImageJ		https://imagei.nih.gov/ii/
R 4.0.1		https://cloud.r-project.org/
tidyyerse (1.3.0)	Wickham	https://www.tidyverse.org/blo
	et al	a/2019/11/tidyverse-1-3-0/
	2019	g, _ 0 10, 11, aug to 100 1 0 0,
ggalluvial	Brunson	http://corybrunson.aithub.io/a
gganavia	et al	galluvial/
	2020	9
Tophat	Trapnell et al.,	https://ccb.jhu.edu/software/t
	2009	ophat/index.shtml
pvclust	Suzuki and	
	Shimodaira, 2006	
stats	R stats package	
AnimalTFDB	Zhang et al., 2012	http://bioinfo.life.hust.edu.cn/
		AnimalTFDB/#!/
Cellranger (3.1.0)		10x genomics
dropEst	Petukhov et al.,	https://github.com/hms-
	2018	dbmi/dropEst
Seurat (3.1.5)	Butler et al., 2018;	https://github.com/satijalab/se
	Stuart et al., 2019	urat
Bioconductor (3.10)	Amezquita et al.,	https://www.bioconductor.org
	2020	
biomaRt	Durinck et al., 2009	https://bioconductor.org/pack
		ages/release/bioc/html/bioma
		Rt.html
Scrublet	Wolock et al., 2019	https://github.com/AllonKleinL
		ab/scrublet
Scanpy	Wolf et al., 2018	https://github.com/theislab/sc
		anpy
fastMNN	Haghverdi et al.,	https://bioconductor.org/pack
	2018	ages/release/bioc/html/batch
	1	l alar html

GImGamPoi	Ahlmann-Eltze et al. 2020	http://bioconductor.org/packa ges/release/bioc/html/glmGa mPoi.html		
presto	Korsunsky et al.,	https://github.com/immunoge		
	2019	nomics/presto		
wot	Schiebinger et al.	https://broadinstitute.github.io		
	2019	/wot/		

1

## 2 LEAD CONTACT AND MATERIALS AVAILABILITY

Further information and requests for resources such as recombinant DNA plasmids
generated in this study should be directed to and will be fulfilled by the Lead Contact,
Clifford J. Tabin (tabin@genetics.med.harvard.edu).

6

## 7 EXPERIMENTAL MODEL AND SUBJECT DETAILS

#### 8 Mouse and chicken embryos

9 Mouse colonies were maintained in the vivarium at the New Research Building of Harvard Medical School. Prx1-CreER-IRES-GFP (hereafter Prx1-GFP) mice were 10 11 provided by Shunichi Murakami (Case Western Reserve University)(Kawanami et al., 2009). Ai9 (Gt[ROSA]26Sor<sup>tm9[CAG-tdTomato]Hze</sup>) and CAG-GFP (C57BL/6-Tg [CAG-12 EGFP<sup>10sb/J</sup>) mouse strains were purchased from the Jackson Laboratory. Ai9 mice 13 14 were crossed with Prx1-GFP mice to obtain Prx1-CreER-IRES-GFP:Rosa-CAG-LSLtdTomato reporter embryos (*Prx1*-tdTomato). White leghorn eggs were obtained from 15 Charles River. Chicken embryos were staged according to the Hamburger and 16 Hamilton stages (HH) (Hamburger and Hamilton, 1951). All animal experiments were 17 performed under the guidelines of the Harvard Medical School Institutional Animal 18 Care and Use Committee. 19

20

#### 21 METHOD DETAILS

#### 22 Embryonic fibroblast isolation

Embryonic fibroblasts were derived from E13.5 *Prx1*-GFP or *Prx1*-tdTomato embryos 1 (the head, neck, limbs, lateral plate mesoderm derived tissues, and internal organs 2 were discarded). The dissected embryos were minced with a razor blade and 3 incubated in 0.25% Trypsin (Sigma) for 15 min. The suspension was plated in Gelatin 4 (Millipore)-coated 15-cm tissue culture dishes in DMEM/10%FBS/1%Pen-Strep media 5 6 (DMEM/FBS). The cells were grown at 37°C in 5% CO<sub>2</sub> until confluent, and GFP- or 7 GFP/tdTomato- negative fibroblasts were collected by a FAC sorter Astrios (Beckman Coulter). After the sorted cells were grown until confluent, the cells were split once 8 9 before being frozen (Passage 3).

10

#### 11 Matrigel coating

200 ul of Matrigel (Corning) is diluted with 200 ul of chilled OPTI-MEM (gibco) (1:1
dilution), and the diluted Matrigel was placed in a well of a 24-well plate (Corning). The
plate was incubated to be gelatinized in a cell culture chamber at 37°C for 30 min.

15

#### 16 Harvest and culture of limb progenitors

Forelimb (FL) buds from E9.5 Prx1-GFP mouse embryos or HH18 GFP-chicken 17 embryos were dissected out and incubated in 0.25% Trypsin for 5-10 min at room 18 temperature to loosen ectodermal tissues. After the surface ectoderm was removed 19 by fine forceps, limb progenitors (LPs) were dissociated gently by pipetting and 20 pelleted by centrifugation. The cells were re-dissociated by culture media, and LPs 21 22 obtained from two limb buds were placed in one well of 24-well plate dishes, a hyaluronan (HA)-based hydrogel (CELENYS) or a well of Matrigel-coated 24-well plate 23 dishes. To make the LP culture media (CFRSY media), DMEM/FBS was 24 supplemented with 3 µM Chir99021 (Tocris), 150 ng/ml Fgf8 (R&D Systems), 25 nM 25

Retinoic acid (Tocris), 5 µM SB431542 (Sigma-Aldrich), 10 µM Y-27632 (Cayman
 Chemical), 55 µM 2-Mercaptoethanol (gibco), and MEM Non-Essential Amino Acids
 Solution (100X, NEAA, gibco). The media was changed every other day until Day6,
 and then changed every day until Day10.

5

## 6 Quantitative PCR (qPCR)

RNA was extracted using Tryzol (Invitrogen) or RNeasy Mini kit (Qiagen). For qPCR 7 of *Lin28a*, RNAs were extracted from FL, HL and flank mesenchyme located between 8 9 FL and HL buds at E9.5 CD1 mouse embryos by using RNeasy Mini kit. To recover RNA from the cells cultured in the HA-hydrogels, the cells in the gels were lysed in 1 10 ml Trizol (for 1 to 5 hydrogels) by vortexing for 5 min. 200 µl of Chloroform (Sigma-11 Aldrich) was added and vortexed for 10 sec, and then incubated for 3 min at room 12 temperature. After centrifugation (10,000 g, 20 min, 4°C), aqueous phase was 13 14 collected, and 500 µl isopropanol was added. After centrifugation and two washes with 80% ethanol, RNA pellets were dissolved in RNase-free water and kept at -80°C until 15 use. The collected RNA was reverse-transcribed by SuperScript III First-Strand 16 Synthesis System (Thermo Fisher). PCR reaction was performed by using Brilliant III 17 Ultra-Fast SYBR Green QPCR kit (Agilent) and CFX Touch Real-Time PCR Detection 18 System (Bio-Rad). Relative expression levels were calculated by the  $\Delta\Delta$ Cq method. 19 Sequences (5'-3') of primers for qPCR are described in Table S4. 20

21

## 22 Plasmid construction

The coding regions of candidate genes were PCR-amplified from mouse embryo derived cDNA or purchased clones (Thermo Scientific). The PCR-amplified sequences were cloned into pDONR221 using the Gateway BP reaction mix (Invitrogen). The

resulting entry clones were then recombined with pMXs-gw (Gift from Shinya 1 Yamanaka; Addgene #18656) using the Gateway LR reaction mix (Invitrogen). For 2 FUW-TetO-Prdm16 and FUW-TetO-Lin41, cDNAs of Prdm16 and Lin41 were amplified 3 by PCR from pMXs-Prdm16 and pMXs-Lin41 inserted to FUW-TetO-MCS (Addgene 4 #84008) using Gibson Assembly Mix (New England Biolabs), respectively. To obtain 5 pT2A-CAGGS-H2B-mCherry-IRES-ZsGreen1 pT2A-CAGGS-EGR1-IRES-6 and 7 ZsGreen1, cDNAs of H2B-mCherry and EGR1 were integrated into pT2A-CAGGS-IRES-ZsGreen1 (Atsuta and Takahashi, 2016). For pBS-cSall4, pBS-cLin28a, pBS-8 9 cLin41 and pBS-cEgr1, the sequences amplified by PCR from HH18 or HH24 FL cDNA libraries that were generated by SuperScript III First-Strand Synthesis System 10 (Thermo Fischer) were cloned into pBS-D (a gift from Dr. Daisuke Saito [Kyushu 11 University]). 12

13

#### 14 Viral production

Plat-E cells (Morita et al., 2000) were grown to 60-70% confluency in 10-cm dishes. 15 pMXs-based retroviral vectors were transfected using Polyethylenimine (PEI, 16 PolyScience). 30 µl of PEI (1 mg/ml) was diluted in 70 µl OPTI-MEM and incubated 17 for 5 min at room temperature. 10 µg plasmid DNA was added to 100 µl OPTI-MEM, 18 and then PEI and plasmid DNA solutions were combined and vortexed vigorously. The 19 20 mixture was incubated for 30 min, and was added to the Plat-E cells. The cells were incubated for 24 hrs, and the media was replaced with 5 ml of fresh DMEM/FBS. The 21 cells were incubated for another 24 hrs. 48 hrs after the initial transfection, the 22 supernatant was collected and filtered. For production of lentiviruses, 293T cells were 23 cultured up to 50-60% confluency in 10-cm dishes. 40 µl of PEI was diluted in 60 µl 24 OPTI-MEM and incubated for 5 min at room temperature. 7.5 µg plasmid DNA carrying 25

the reprogramming factor, 4.5 µg psPAX2 and 1.5 µg VSV-G plasmids were added to
PEI solution, and the transfectant was incubated for 30 min. Then, the mixture was
added to 293T cells, and 48 hrs after the transfection, the supernatant was harvested
and filtrated through 0.45-µm SFCA syringe filters (Corning).

5

#### 6 **Reprogramming assays:**

#### 7 Reprogramming for mouse embryonic fibroblasts using HA-hydrogels

At 60-70% confluency, mouse embryonic fibroblasts (Prx1-GFP negative) were 8 9 cultured in the supernatant of retroviruses carrying the candidate factors for 24 hrs in the presence of Polybrene (8 µg/ml; Sigma-Aldrich) at 37°C (Day 0), and the media 10 was replaced with DMEM/FBS containing 2-Mercaptoethanol and NEAA (Day 0). 48 11 hrs after viral infection, the media was supplemented with 3 µM Chir99021, 150 ng/ml 12 Fgf8, 25 nM Retinoic acid, 10 µM Y-27632, 55 µM 2-Mercaptoethanol, and Non-13 14 Essential Amino Acids (CFRY media; Day2). 48 hrs after CFRY administration, the viral infected cells were detached by Trypsin/EDTA, and the cells from each well of 24-15 well plates were suspended in 20 µl of CFRSY media (CFRY plus 5 µM SB431542). 16 17 Subsequently, the cell suspension was loaded on the top of the HA-gels, and the gels were incubated for 30 min at 37°C. After incubation, the HA-gels were placed in 200 µl 18 of CFRSY media, and the media was changed with the fresh CFRSY media every two 19 days from Day4 to 10, every day from Day11 to 14. See also the schematics in Fig. 20 1G. 21

#### 22 Reprogramming for mouse embryonic fibroblasts using Matrigel

At 60-70% confluency, GFP/tdTomato-negative fibroblasts from *Prx1*-tdTomato mice
were cultured in the supernatant of lentiviruses carrying Prdm16, Zbtb16, Lin28a, and
Lin41 (PZLL) for 24 hrs in the presence of Polybrene (8 µg/ml) at 37°C (Day -1). The

media was replaced with DMEM/FBS containing 2 µg/ml of Doxycycline (Dox; Sigma-1 Aldrich), 2-Mercaptoethanol and NEAA (Day 0). Next day the media was replaced 2 with CFRY media containing Dox (CFRYD media; Day 1). 48 hrs after Dox 3 administration, the cells were dissociated with TryPLE Express, and plated on Matrigel. 4 The media was supplemented with CFRSYD media (Day 3), and was changed with 5 the fresh CFRSYD media every two days from Day4 to 10, every day from Day11 to 6 7 14. 4-hydroxy tamoxifen (Calbiochem) was added to the media at Day 12 and Day 13, to induce *Prx1*-tdTomato. See also the schematics in Fig. 4A and S9. 8

#### 9 **Reprogramming for human adult fibroblasts using Matrigel**

Similarly to mouse cell reprogramming, human fibroblasts (iXCells Biotechnologies) were transduced with lentiviruses to misexpress PZLL at 60-70% confluency. After 2day-culture of DMEM/FBS/Dox and another 2day-culture with CFRY/Dox, the cells were transferred onto Matrigel bed and cultured for additional 14 days with CFRSY/Dox media. The total culture term was 18 days.

15

#### 16 Immunostaining

For immunohistochemical staining, the following antibodies were used as described 17 previously (Atsuta et al., 2019): anti-GFP (1:1000; Sigma), anti-Lhx2 (1:500; Millipore-18 Sigma), anti-Sall4 (1:500; Abcam), anti-Sox9 (1:500; Millipore-Sigma), anti-EGR1 19 20 (1:250; Thermo Fisher), anti-Collagen type I (1:100; Rockland), anti-Nmyc (1:500; Santa Cruz Biotechnology), anti-Tfap2c (1:500; Santa Cruz Biotechnology), anti-21 Msx1/2 (1:100; DSHB), anti-pH3 (1:500; Millipore-Sigma), anti-Collagen type II (1:100; 22 23 DSHB), anti-MHC (1:50; DSHB), and anti-Human nuclei (1:250; Millipore-Sigma). For staining of Col2A1, an antigen retrieval using Target Retrieval Solution (DAKO) was 24 performed in advance of blocking. To stain the 3D-cultured cells embedded in the HA-25

gel or Matrigel, the cells in the gels were placed in 1% PFA/PBS overnight at 4°C. The
next day, the gels with the cells were incubated in 0.5% Triton X-100 (SigmaAldrich)/PBS for 15 min at room temperature, and then in 1% Blocking Reagent
(Roche)/TNT buffer for 1 hr at room temperature, followed by primary and secondary
antibody incubations. The stained cells were placed on a glass-bottom dish (MatTek),
and images were taken by the confocal microscope LSM710 (Carl Zeiss).

7

## 8 Micromass culture and Alcian blue staining

Micromass culture and alcian blue staining were performed as previously described
(Atsuta et al., 2019). Fibroblasts and LPs from E9.5 *Prx1*-GFP mouse forelimb (FL)
buds, and *Prx1*-GFP positive reprogrammed cells were used to generate micromass
cultures. ~5 x 10<sup>4</sup> cells per 20 µl of DMEM/FBS were dropped into each well of 96well. After being attached, the cells were cultured in the presence of CFRSY for 2 days,
and then in DMEM/FBS for 8 days.

15

#### 16 **Probes and** *in situ* hybridization

Whole mount *in situ* hybridization for HH15 and HH17 chicken embryos was performed
as described in (Tonegawa et al., 1997). cDNA sequences for chicken *Sall4*, *Lin28a*, *Lin41* and *Egr1* are described in Supplemental Table 4. RNA probes were transcribed
using DIG-RNA labeling Mix (Roche) and T3 RNA polymerase (Roche), and the
probes were detected with NBT/BCIP solution (Roche).

22

#### 23 In ovo electroporation

The *in ovo* electroporation was performed as previously described (Atsuta et al., 2019).
Briefly, eggs were incubated for approximately 54 hrs at 38°C. DNA solution was

1	prepared at 4 $\mu$ g/µl, and injected into the coelomic cavity of HH14 embryos. Three
2	electric pulses of 50 V, 2 ms, were given, followed by 7 pulses of 5 V, 10 ms, with 10-
3	ms interval between pulses (Super Electroporator NEPA21-type II, NEPA GENE).
4	
5	Tamoxifen and 4-Hydroxy Tamoxifen (4-OHT) treatment
6	Tamoxifen was dissolved in corn oil (Sigma-Aldrich), and 1 mg of tamoxifen was given
7	to E8.5 $Prx1$ -tdTomato pregnant dams by intraperitoneal injections; 2 $\mu$ M of 4-OHT
8	(Calbiochem) was used for reprogramming experiments to activate CreER proteins.
9	
10	Cell transplantation to chicken embryos
11	For cell injection, LPs from E9.5 CAG-GFP mouse FL, fibroblasts infected with
12	lentiviruses carrying mCherry, and Prx1-tdTomato positive reprogrammed cells were
13	used. The LPs form 10 FL buds were dissociated in 100 $\mu I$ of DMEM/FBS. The
14	mCherry-expressing fibroblasts and the tdTomato-reprogrammed cells were retrieved
15	from one well of 24-well plates using TryPLE Express, and after pelleted, the cells
16	were dissociated with 50 $\mu I$ of DMEM/FBS. The cell suspension was injected in FL
17	buds of HH20 chicken embryos, and the embryos were harvested at HH32.
18	
19	RNA-Seq library preparation
20	Familiand chicken ages were insubstant of 2000. El (III, huster and flamb/sach

Fertilized chicken eggs were incubated at 38°C. FL/HL buds and flank/neck mesenchyme were dissected from HH18/19 embryos. Neck tissue was located in the mesenchyme directly above the FL bud. Loose ectodermal tissues were removed and remaining mesenchyme was placed in TRIzol (Invitrogen) for RNA extraction. RNA-Seq on chick RNA was carried out as previously described (Christodoulou et al., 2014). Libraries were constructed without RNA or cDNA fragmentation and did not include

normalization. Uniform amplification was achieved with amplification cycling before
the reaction reached saturation, as determined by qPCR. Following Hi-Seq (Illumina)
sequencing, reads were aligned using Tophat (version 1.4.0) (Trapnell et al., 2009).

#### 5 Dissociation and FAC-sorting of 3D cultured cells before scRNA-seq

For sorting reprogrammed *Prx1*-GFP or *Prx1*-tdTomato cells, a FACS sorter Astrios 6 7 (Beckman Coulter) or On-chip Sort HSG (On-chip Biotechnologies) was used. After washing with PBS, the cells cultured in the HA-gels or on Matrigel were incubated in 8 9 TryPLE Express (gibco) for 30 min at 37°C. The cell suspension was pipetted with cut P1000 pipette tips every 10 min, to completely dissociate the cell clusters. The 10 suspension was filtrated by 100 µm Cell strainers (Falcon) and 40 µm Cell strainers 11 (VWR), and cells were pelleted by centrifugation (400 x g for 5 min). The pellets were 12 dissociated by DRAQ5/DAPI in 0.1% BSA/PBS and incubated for 5 min before the 13 14 sorting. . DRAQ5-positive, DAPI-negative cells were sorted for cells on reprogramming at day 2, 4, 8. For HA-gel reprogrammed cells at day 14, additional gating on GFP 15 channel derived GFP-positive and GFP-negative samples. For Matrigel-derived day 16 17 14 reprogrammed cells for PZL- as well as PZLL- factors, only GFP-positive cells were collected. DRAQ5-positive, DAPI-negative, Matrigel-derived day 8 cultured E9.5 and 18 E10.5 limb progenitors were collected. The E9.5 cultured limb progenitors were 19 subject to 4-OHT, such that large fraction were tdtomato-positive, but the cells were 20 regardless of tdTomato-positivity. DRAQ5-positive, DAPI-negative, 21 collected tdTomato-positive cells were sorted for the limb mesenchyme cells for E10.5, E11.5 22 as well as E12.5 cells. For E9.5 limb progenitors, samples were collected without 23 tdTomato gating to maximize yield. 24

25

#### 1 Single-cell RNA-Seq library preparation:

#### 2 InDrops scRNA-seq

3 LPs were obtained from E9.5 and E10.5 mouse FL buds. HA-gel derived 4 reprogrammed cells (PZL-factor) and empty controls, as well as CFSRY cultured 5 NonLFs were collected and processed individually. cDNA library preparation was 6 performed by Single Cell Core (HMS).

#### 7 10xGenomics scRNA-seq

FAC-sorted LPs were obtained from E9.5 and E10.5 *Prx1*-tdTomato mouse FL buds.
All libraries included about 10-15% of MEF cells to mitigate batch effect. cDNA library
preparation was performed by using 10x Genomics Chromium Single Cell 3' (v.3
Chemistry; 10x Genomics) gene-expression kit, according to manufacturer's
instructions. Gel beads in emulsion (GEM) formation was performed with a Chromium
Controller (10x Genomics; Biopolymer Facility at HMS). cDNA library was prepared in
house.

15

#### 16 Single-cell RNA-Seq sequencing

InDrops libraries were sequenced with Illumina Nextseg 500 platform, using paired-17 end reads with the read length configuration recommended by InDrops (61bp for 18 transcript, 14bp for barcode and UMI, 8bp i7 index for part of barcode, 8bp i5 index for 19 20 sample index). 10x Genomics libraries were sequenced with Illumina Nextseq 500 platform as well as Novaseg 6000 platform. For Nextseg 500, recommended 21 configuration by 10x Genomics (28bp for cell barcode 1 and UMI, 8bp i7 index for 22 23 sample index, 98bp for transcript) we used. For Novaseq, 150bp paired-end sequencing with sample i7 index were used (compatible with the 10x Genomics 24 cellranger count matrix mapping software). 25

#### 1

#### 2 QUANTIFICATION AND STATISTICAL ANALYSIS

#### 3 RNA-Seq analyses

Analysis on transcriptome gene expression was conducted in R. The pvclust package
(Suzuki and Shimodaira, 2006) was used to perform principal component analysis.
The AnimalTFDB (Zhang et al., 2012) online resource was used to select transcription
factors from the chick and mouse genomes.

8

#### 9 Single-cell RNA-Seq analyses

#### 10 Transcriptome annotation

For mouse samples, Ensembl release 98 mm10 transcriptome was used as base 11 transcriptome annotation, with pseudogenes filtered from the GTF file using cellranger 12 mkgtf command. For retroviral infected hyaluronan samples, transgenes for human 13 Lin28a, EGFP (for Prx1GFP transgene) was added to generate custom transcriptome 14 annotation for guantification for reprogrammed cells. For lentiviral infected Matrigel 15 samples, transgenes for EGFP (for Prx1GFP transgene), rtTA, and human Lin41 as 16 well as PLZF, and 3'UTR sequences of WPRE were added to generate custom 17 transcriptome annotation for quantification for reprogrammed cells. The limb 18 progenitor cells were subject to the same transcriptome annotation (yielding zero 19 20 counts for the transgenes). All four human samples were multiplexed with mouse and chick samples (Supplementary Table 1). The chick data was not presented in this 21 manuscript. Thus, for species demultiplexing, Ensembl release 99 hg38 transcriptome, 22 23 Ensembl release 98 Gallus gallus-6.0 transcriptome and the filtered Ensembl release 98 mm10 transcriptome was merged using the cellranger mkgtf command to generate 24 human-mouse-chick transcriptome for initial mapping for demultiplexing. For human-25

specific mapping, the filtered hg38 transcriptome with transgenes for EGFP, rtTA, and
mouse Prdm16 and mouse Lin28a were added. For the limb progenitor samples
processed with 10X genomics, tdtomato, EGFP transgenes were added for mapping.

#### 5 InDrop preprocessing

Sequencing results were demultiplexed by dropTag from dropEst package (Petukhov
et al. 2018). The demultiplexed reads were aligned with STAR aligner (Dobin et al.
2013). The aligned reads were split into forward and reverse alignment, since InDrops
is directional. The resulting forward and reverse alignment files were quantified using
dropEst package including directional UMI correction option (Petukhov et al. 2018)
with transcriptome annotation split into forward and reverse direction to avoid mapping
of antisense reads.

13

#### 14 **10x data processing**

Sequencing results were demultiplexed by cellranger and aligned using cellranger count (internally by STAR aligner (Dobin et al. 2013)). For the four libraries that needed species demultiplexing, cellular barcodes that had less than 5% of UMI counts from other species were selected for subsequent mapping with the corresponding species transcriptome (see above).

20

#### 21 Quality control and clustering

Cellular barcodes with high mitochondrial content (>15%), high hemoglobin gene
count (>10%) and low gene counts (<1,200) were filtered out. All libraries were subject</li>
to doublet detection via Scrublet (Wolock et al. 2019). The overall findings were not
sensitive to the identified doublets. Batch effect was assessed by simply merging the

individual UMI count matrices for clustering, which revealed dominant batch effect by 1 technology (InDrop vs 10X) and time (the last 10X batch was separated by several 2 months due to the pandemic). Thus, Seurat v3 integration procedure (SCTransform 3 based) was applied (Stuart, Butler et al. 2019) with 30 dimensions for the individual 4 batches. Further, cell cycle effect, a fraction of mitochondrial genes was regressed out. 5 Principal component analysis (PCA) was performed on the integrated, scaled features 6 7 for dimensional reduction and Uniform Manifold Approximation and Projection (UMAP) (McInnes et al. 2018) was used primarily for the cellular embedding coordinates. 8 9 Leiden algorithm was applied on the neighbor graph with 10 iterations (Seurat default) to derive cluster boundaries (Traag et al. 2019). For all steps of clustering, the number 10 of principal components were determined by observing the "elbow" of variance 11 explained by the principal components, however, robustness of the relationship was 12 confirmed by changing the number of principal components and deriving essentially 13 similar relationship. Thus, 20 principal components were used for downstream 14 processing. Resolution parameter of 0.2 was used for gross subdivision of all cells into 15 7 clusters (Fig. 5), and a resolution of 0.4 was used for leiden clustering for differential 16 expression analysis and trajectory inference for Partition-based graph abstraction 17 (PAGA) (Wolf et al. 2019) (Fig. 6). For presenting the embedding of human cell results 18 only, the UMAP plot was based on fastMNN batch correction (Haghverdi et al. 2018). 19 20

#### 21 Differentially expressed gene analysis, Gene set overlap analysis

Differentially expressed gene analysis (Fig. 5C, S13, Supplementary Table 2) were conducted with the glmGamPoi package (Ahlmann-Eltze et al., 2020) modelling the the batch effect as an additive latent variable and p-values were adjusted as pseudobulk procedure treating each biological samples as one unit rather than cells,

yielding adjusted p-values (Benjamini-Hochberg). For Fig. 5C, cells from specific 1 clusters were subsetted and further filtered such that the pseudobulk samples will have 2 at least more than 100 cells, and instead of cluster labels, the sample origin (primary, 3 PZL, PZLL) were used as a model variable. Similarly, for Fig. S13A, cells from specific 4 clusters were subsetted and filtered as well and culture condition (Immediately 5 harvested or 3D cultured for 8 days) were assigned for the samples as modelling 6 7 variable. For those differentially expressed genes, the list were compared to the curated gene sets (Fig. S13B), or Gene Ontology (GO) terms (Biological process) for 8 9 overlap by chance using MSigDB (Subramanian et al. 2005; Liberzon et al. 2011). To derive differentially expressed genes for Fig. 6D and Supplementary Table 3, simple 10 weighted t-test based differential expression analysis provided by the Waddington 11 Optimal Transport (WOT) analysis package was used, with the full reservation that the 12 p-values will be artificially low. 13

14

#### 15 Waddington Optimal Transport (WOT) analysis

The Waddington Optimal Transport analysis estimates the growth rate based on the 16 cell cycle as well as apoptosis gene scores, calculated by z-score normalization ( 17 Schiebinger et al. 2019). Combat batch correction (Johnson et. al 2007) provided by 18 scanpy framework was applied to the log-normalized UMI expression level before 19 20 deriving the z-scores. The resulting cell cycle score as well as apoptosis score was used to infer the initial cell growth estimates, and growth fraction estimation as well as 21 transport maps for control virus-infected time series, PZL (Prdm16+Ztbt16+Lin28a; 3-22 23 factor lentiviral expression)-infected time series. PZLL (Prdm16+Ztbt16+Lin28a+Lin41; 4-factor lentiviral expression)-infected time series 24 were calculated separately with the following parameters: epsilon=0.05, lambda1=1, 25

lambda2=50, growth iteration=3. The choice of parameters were not sensitive for the 1 Since the day 8 PZL scRNA-seg had very low coverage, 2 overall findings. transcriptomes from day 8 PZLL-infected cells that do not show expression of 3 transgene human Lin41 were included for the inference of this intermediate stage 4 inference. Based on the transport maps, the ancestor and descendant relationship 5 was calculated resulting in transition matrices between time points. The resulting 6 7 transition tables were used to construct the alluvial diagrams used in Fig. 6B abd Fig. 14D, with the ggalluvial package (Brunson et al. 2020). The cell sets for each high 8 9 resolution leiden clusters (resolution=0.4) at Day 14 were defined as final fates, and the fate probability, weighted mean expression at different time points for individual 10 genes was calculated for Fig. 6D and Fig. S14, S15 and Supplementary Table 3. 11

12

#### 13 Human/Mouse scRNA-seq data processing

The four human UMI count matrices were merged first and only orthologous genes (1:1 matching) from the human transcriptome based on biomaRt (Durinck et al., 2009) were translated into mouse genes. The resulting matrix were integrated with the mouse libraries treating the human libraries as a separate batch (SCTransform-based Seurat integration). All subsequent clustering steps were identical to the mouse-only analysis.

20

#### 21 DATA AND CODE AVAILABILITY

24

#### 25 **REFERENCES**

1	Agarwal, P.,	Wylie, J.N.,	Galceran,	J., Arkhitko,	O., Li,	C., Deng,	C.,	Grosschedl,	R.,
---	--------------	--------------	-----------	---------------	---------	-----------	-----	-------------	-----

- 2 and Bruneau, B.G. (2003). *Tbx5* is essential for forelimb bud initiation following
- 3 patterning of the limb field in the mouse embryo. Development *130*, 623-633.
- Ahlmann-Eltze, C. and Huber, W. (2020). glmGamPoi: Fitting gamma-poisson
  generalized linear models on single cell count data. Bioinfomatics, btaa1009.
- 6 Amezquita, R.A., Lun, A.T.L., Becht, E., Carey, V.J., Carpp, L.N., Marini, F., Rue-
- Albrecht, K., Risso, D., Soneson, C., Waldron, L., *et al.* (2020). Orchestrating singlecell analysis with Bioconductor. Nat. Methods *17*, 137-145.
- 9 Atsuta, Y., and Takahashi, Y. (2016). Early formation of the Müllerian duct is regulated
- by sequential actions of BMP/Pax2 and FGF/Lim1 signaling. Development 143, 3549-
- 11 3559.
- 12 Atsuta, Y., Tomizawa, R.R., Levin, M., and Tabin, C.J. (2019). L-type voltage-gated
- 13 Ca<sup>2+</sup> channel CaV1.2 regulates chondrogenesis during limb development. Proc. Natl.
- 14 Acad. Sci. USA *116*, 21592-21601.
- Barna, M., Hawe, N., Niswander, L., and Pandolfi, P.P. (2000). Plzf regulates limb and
  axial skeletal patterning. Nat. Genet. *25*, 166-172.
- Becht, E., McInnes, L., Healy, J., Dutertre, C.A., Kwok, H., Ng, L.G., Ginhoux, F., and
- Newell, E. (2018). Dimensionality reduction for visualizing single-cell data using UMAP.
  Nat. Biotechnol. *37*, 38-44.
- Bohm, J., Buck, A., Borozdin, W., Mannan, A.U., Matysiak-Scholze, U., Adham, I.,
- Schulz-Schaeffer, W., Floss, T., Wurst, W., Kohlhase, J., et al. (2008). Sall1, sall2, and
- sall4 are required for neural tube closure in mice. Am. J. Pathol. *173*, 1455-1463.
- Brunson, J. C. (2020). ggalluvial: layered grammar for Alluvial plots. J. Open Source
  Software 5, 2017.
- Buganim, Y., Markoulaki, S., van Wietmarschen, N., Hoke, H., Wu, T., Ganz, K.,

Akhtar-Zaidi, B., He, Y., Abraham, B.J., Porubsky, D., *et al.* (2014). The developmental
 potential of iPSCs is greatly influenced by reprogramming factor selection. Cell Stem
 Cell *15*, 295-309.

Butler, A., Hoffman, P., Smibert, P., Papalexi, E., and Satija, R. (2018). Integrating
single-cell transcriptomic data across different conditions, technologies, and species.
Nat. Biotechnol. *36*, 411-420.

Caiazzo, M.O., Y.; Ranga, A.; Piersigilli, A.; Tabata, Y.; Lutolf, M. P. (2016). Defined
three-dimensional microenvironments boost induction of pluripotency. Nat. Mater. *15*,
344-352.

Capellini, T. D., Giacomo, G. D., Salsi, V. Brendolan, A., Ferretti, E., Srivastava, D.
Zppavigna, V. and Selleri, L. (2006). *Pbx1/Pbx2* requirement for distal limb patterning
is mediated by the hierarchical control of Hox gene spatial distribution and *Shh*expression. Development *133*, 2263-2273.

Chapman, S.C., Lawson, A., Macarthur, W.C., Wiese, R.J., Loechel, R.H., BurgosTrinidad, M., Wakefield, J.K., Ramabhadran, R., Mauch, T.J., and Schoenwolf, G.C.
(2005). Ubiquitous GFP expression in transgenic chickens using a lentiviral vector.
Development *132*, 935-940.

Chen, H., Lun, Y., Ovchinnikov, D., Kokubo, H., Oberg, K., Pepicelli, C., Gan, L., Lee,
B., and Johnson, R. (1998). Limb and kidney defects in *Lmx1b* mutant mice suggest
an involvement of *LMX1B* in human nail patella syndrome. Nat. Genet. *19*, 51-55.

Chen, Y., and Gridley, T. (2013). Compensatory regulation of the Snai1 and Snai2
genes during chondrogenesis. J. Bone Miner. Res. 28, 1412-1421.

Chen, Y., Xu, H. and Lin, G. (2017). Generation of iPSC-derived limb progenitor-like
cells fro stimulating phalange regeneration in the adult mouse. Cell Disco. *3*, Article
number: 17046.

- 1 Chi, J., and Cohen, P. (2016). The multifaceted roles of PRDM16: adipose biology
- 2 and beyond. Trends. Endocrin. Met. 27, 11-23.
- 3 Christodoulou, D.C., Wakimoto, H., Onoue, K., Eminaga, S., Gorham, J.M., DePalma,
- 4 S.R., Herman, D.S., Teekakirikul, P., Conner, D.A., McKean, D.M., et al. (2014).
- 5 5'RNA-Seq identifies Fhl1 as a genetic modifier in cardiomyopathy. J Clin. Invest. *124*,
  1364-1370.
- 7 Cooper, K.L., Hu, J.K., ten Berge, D., Fernandez-Teran, M., Ros, M.A., and Tabin, C.J.
- 8 (2011). Initiation of proximal-distal patterning in the vertebrate limb by signals and
  9 growth. Science *332*, 1083-1086.
- 10 Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P.,
- Chaisson, M., and Gingeras, T.R. (2013). STAR: ultrafast universal RNA-seq aligner.
  Bioinformatics *29*, 15-21.
- Dupé, V., Ghyselinck, N.B., Thomazy, V., Nagy, L., Davies, P.J., Chambon, P., and
  Mark, M. (1999). Essential roles of retinoic acid signaling in interdigital apoptosis and
- 15 control of BMP-7 expression in mouse autopods. Dev. Biol. 208, 30-43.
- 16 Durinck, S., Spellman, P.T., Birney, E., and Huber, W. (2009). Mapping identifiers for
- the integration of genomic datasets with the R/Bioconductor package biomaRt. Nat.
  Protoc. *4*, 1184-1191.
- Ecsedi, M., and Grosshans, H. (2013). LIN-41/TRIM71: emancipation of a miRNA
  target. Genes Dev. 27, 581-589.
- Gao, Y., Lan, Y., Liu, H., and Jiang, R. (2011). The zinc finger transcription factors Osr1
- and Osr2 control synovial joint formation. Dev. Biol. 352, 83-91.
- Gros, J., and Tabin, C.J. (2014). Vertebrate limb bud formation is initiated by localized
  epithelial-to-mesenchymal transition. Science *343*, 1253-1256.
- Haghverdi, L., Lun, A.T.L., and Marioni, J.C. (2018). Batch effects in single-cell RNA-

- 1 sequencing data are corrected by matching mutual nearest neighbors. Nat. Biotechnol.
- 2 36, 421-427.
- Hamburger, V., and Hamilton, H.L. (1951). A series of normal stages in the
  development of the chick embryo. J. Morphol. *88*, 49-92.
- Healy, C., Uwanogho, D., and Sharpe, P.T. (1999). Regulation and role of Sox9 in
  cartilage formation. Dev. Dyn. *215*, 69-78.
- 7 Izpisua Belmonte, J.C., Brown, J.M., Crawley, A., Duboule, D., and Tickle, C. (1992).
- 8 Hox-4 gene expression in mouse/chicken heterospecific grafts of signalling regions to
- 9 limb buds reveals similarities in patterning mechanisms. Development *115*, 553-560.
- Johnson, W. E., Li, C. and Rabinovic, A. (2007). Adjusting batch effects in microarray
- expression data using empirical Bayes methods. Biostatistics *8*, 118-127.
- 12 Kawamura, T., Suzuki, J., Wang, Y.V., Menendez, S., Morera, L.B., Raya, A., Wahl,
- 13 G.M., and Izpisua Belmonte, J.C. (2009). Linking the p53 tumour suppressor pathway
- to somatic cell reprogramming. Nature *460*, 1140-1144.
- Kawanami, A., Matsushita, T., Chan, Y.Y., and Murakami, S. (2009). Mice expressing
- 16 GFP and CreER in osteochondro progenitor cells in the periosteum. Biochem. Biophys.
- 17 Res. Commun. 386, 477-482.
- Korsunsky, I., Nathan, A., Millard, N., and Raychaudhuri, S. (2019). Presto scales
  Wilcoxon and auROC analyses to millions of observations. bioRxiv.
- Lancman, J.J., Caruccio, N.C., Harfe, B.D., Pasquinelli, A.E., Schageman, J.J.,
- Pertsemlidis, A., and Fallon, J.F. (2005). Analysis of the regulation of *lin-41* during
  chick and mouse limb development. Dev. Dyn. *234*, 948-960.
- Li, Y., Toole, B.P., Dealy, C.N., and Kosher, R.A. (2007). Hyaluronan in limb morphogenesis. Dev. Biol. *305*, 411-420.
- Liberzon, A., Subramanian, A., Pinchback, R., Thorvaldsdóttir, H., Tamayo, P., and

- 1 Mesirov, J. P. (2011). Molecular signatures database (MSigDB) 3.0. Bioinformatics 27,
- 2 1739-1740.
- Lin, G., Chen, Y., and Slack, J.M.W. (2013). Imparting regenerative capacity to limbs
  by progenitor cell transplantation. Dev. Cell *24*, 41-51.
- Lin, X., Huang, J., Chen, T., Wang, Y., Xin, S., Li, J., Pei, G., and Kang, J. (2008).
  Yamanaka factors critically regulate the developmental signaling network in mouse
  embryonic stem cells. Cell Res. *18*, 1177-1189.
- 8 Madl, C.M., LeSavage, B.L., Dewi, R.E., Dinh, C.B., Stowers, R.S., Khariton, M.,
- 9 Lampe, K.J., Nguyen, D., Chaudhuri, O., Enejder, A., *et al.* (2017). Maintenance of
  10 neural progenitor cell stemness in 3D hydrogels requires matrix remodelling. Nat.
  11 Mater. *16*, 1233-1242.
- Melton, C., Judson, R. L. and Blelloch, R. (2010). Opposing microRNA families regulate self-renewal in mouse embryonic stem cells. Nature *463*, 621-626.
- Mori, S., Sakakura, E., Tsunekawa, Y., Hagiwara, M., Suzuki, T., and Eiraku, M. (2019).
- 15 Self-organized formation of developing appendages from murine pluripotent stem cells.
- 16 Nat. Commun. *10*, Article number: 3802.
- Morita, S., Kojima, T., and Kitamura, T. (2000). Plat-E: an efficient and stable system
  for transient packaging of retroviruses. Gene Ther. 7, 1063-1066.
- Nguyen, D.T.T., Richter, D., Michel, G., Mitschka, S., Kolanus, W., Cuevas, E., and
  Wulczyn, F.G. (2017). The ubiquitin ligase LIN41/TRIM71 targets p53 to antagonize
  cell death and differentiation pathways during stem cell differentiation. Cell Death
  Differ. *24*, 1063-1078.
- Nishimoto, S., Minguillon, C., Wood, S., and Logan, M.P. (2015). RA acts in a coherent
  feed-forward mechanism with Tbx5 to control limb bud induction and initiation. Cell
  Rep. *12*, 879-891.

1 Petukhov, V., Guo, J., Baryawno, N., Severe, N., Scadden, D.T., Samsonova, M.G.,

and Kharchenko, P.V. (2018). dropEst: pipeline for accurate estimation of molecular
counts in droplet-based single-cell RNA-seq experiments. Genome Biol. *19*, Article
number: 78.

Rao, N., Jhamb, D., Milner, D. J., Li, B., Song, F., Wang, M., Voss, S. R., Palakal, M.,
King, M. W., Saranjami, B., Nye, H. L., Cameron, J. A., and Stocum, D. L. (2009).
Proteomic analysis of blastema formation in regenerating axolotl limbs. BMC Biol. *7*,
83.

9 Rodriguez-Esteban, C., Schwabe, J.W., Pena, J.D., Rincon-Limas, D.E., Magallón, J.,

Botas, J., and Izpisúa Belmonte, J.C. (1998). *Lhx2*, a vertebrate homologue of
 *apterous*, regulates vertebrate limb outgrowth. Development *125*, 3925-3934.

Rodriguez-Esteban, C., Schwabe, J. W. R., La Pena, D. L., Rincon-Limas, D. E.,
Magallón, J., Botas, J. and Izpisua Belmonte, J.C. (1998). *Lhx2*, a vertebrate
homologue of *apterous*, regulates vertebrate limb outgrowth. Development *125*, 3925-

15 3934.

Ros, M.A., Lyons, G.E., Mackem, S., and Fallon, J.F. (1994). Recombinant limbs as a
model to study homeobox gene regulation during limb development. Dev. Biol. *166*,
59-72.

Schiebinger, G., Shu, J., Tabaka, M., Cleary, B., Subramanian, V., Solomon, A., Gould,
J., Liu, S., Lin, S., Berube, P., *et al.* (2019). Optimal-transport analysis of single-cell
gene expression identifies developmental trajectories in reprogramming. Cell *176*,
928-943.

Schweitzer, R., Chyung, J.H., Murtaugh, L.C., Brent, A.E., Rosen, V., Olson, E.N.,
Lassar, A., and Tabin, C.J. (2001). Analysis of the tendon cell fate using Scleraxis, a
specific marker for tendons and ligaments. Development *128*, 3855-3866.
Spyrou, J., Gardner, D.K., and Harvey, A.J. (2019). Metabolism is a key regulator of 1 induced pluripotent stem cell reprogramming. Stem Cells Int. 2019. Article ID: 7360121. 2 Stadtfeld, M., Maherali, N., Breault, D.T., and Hochedlinger, K. (2008). Defining 3 molecular cornerstones during fibroblast to iPS cell reprogramming in mouse. Cell 4 Stem Cell 2, 230-240. 5 Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck III, W.E., Hao, 6 7 Y., Stoecklus, M., Smibert, P., and Satija, R. (2019). Comprehensive integration of single-cell data. Cell 177, 1888-1902. 8 9 Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., and Mesirov, J. P. (2005). 10 Gene set enrichment analysis: a knowledge-based approach for interpreting genome-11 wide expression profiles. Proc Natl Acad Sci U S A 102, 15545-15550. 12 Suzuki, R., and Shimodaira, H. (2006). Pvclust: an R package for assessing the 13 14 uncertainty in hierarchical clustering. Bioinformatics 22, 1540-1542. Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent stem cells from 15 mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676. 16 Takahashi, K., and Yamanaka, S. (2015). A developmental framework for induced 17 pluripotency. Development 142, 3274-3285. 18 Takeuchi, J.K., Koshiba-Takeuchi, K., Suzuki, T., Kamimura, M., Ogura, K., and Ogura, 19 T. (2003). Tbx5 and Tbx4 trigger limb initiation through activation of the Wnt/Fgf 20 signaling cascade. Development 130, 2729-2739. 21

Tarchini, B., Duboule, D., and Kmita, M. (2006). Regulatory constraints in the evolution
of the tetrapod limb anterior-posterior polarity. Nature *443*, 985-988.

Tonegawa, A., Funayama, N., Ueno, N., and Takahashi, Y. (1997). Mesodermal subdivision along the mediolateral axis in chicken controlled by different

73

- 1 concentrations of BMP-4. Development *124*, 1975-1984.
- 2 Traag, V.A., Waltman, L., and van Eck, N.J. (2019). From Louvain to Leiden:
- 3 guaranteeing well-connected communities. Sci. Rep. 9, Article number: 5233.
- 4 Trapnell, C., Pachter, L., and Salzberg, S.L. (2009). TopHat: discovering splice
  5 junctions with RNA-Seq. Bioinformatics 25, 1105-1111.
- 5 Tschopp, P., Sherratt, E., Sanger, T.J., Groner, A.C., Aspiras, A.C., Hu, J.K., Pourquie,
- 7 O., Gros, J., and Tabin, C.J. (2014). A relative shift in cloacal location repositions
- 8 external genitalia in amniote evolution. Nature *516*, 391-394.
- 9 Tsialikas, J., and Romer-Seibert, J. (2015). LIN28: roles and regulation in development
- 10 and beyond. Development *142*, 2397-2404.
- 11 Vierbuchen, T., Ostermeier, A., Pang, Z.P., Kokubu, Y., Südhof, T.C., and Wernig, M.
- (2010). Direct conversion of fibroblasts to functional neurons by defined factors.
  Nature *463*, 1035-1041.
- 14 Viswanathan, S.R., Daley, G.Q., and Gregory, R.I. (2008). Selective blockade of 15 microRNA processing by Lin28. Science *320*, 97-100.
- Wang, T., Shi, S., and Sha, H. (2013). MicroRNAs in regulation of pluripotency and
  somatic cell reprogramming. RNA Biol. *10*, 1255-1261.
- Watanabe, K., Ueno, M., Kamiya, D., Nishiyama, A., Matsumura, M., Wataya, T.,
  Takahashi, J.B., Nishikawa, S., Nishikawa, S., Muguruma, K., *et al.* (2007). A ROCK
  inhibitor permits survival of dissociated human embryonic stem cells. Nat. Biotechnol.
- 21 25, 681-686.
- Wolf, F.A., Angerer, P., and Theis, F.J. (2018). SCANPY: large-scale single-cell gene
  expression data analysis. Genome Biol. *19*, Article number: 15.
- 24 Wolf, F.A., Hamey, F.K., Plass, M., Solana, J., Dahlin, J.S., Göttgens, B., Rajewsky,
- N., Simon, L., and Theis, F.J. (2019). PAGA: graph abstraction reconciles clustering

74

1 with trajectory inference through a topology preserving map of single cells. Genome

2 Biol. 20, Article number: 59.

- Wolock, S.L., Lopez, R., and Klein, A.M. (2019). Scrublet: computational identification
  of cell doublets in single-cell transcriptomic data. Cell Syst. *8*, 281-291.
- 5 Worringer, K.A., Rand, T.A., Hayashi, Y., Sami, S., Takahashi, K., Tanabe, K., Narita,
- 6 M., Srivastava, D., and Yamanaka, S. (2013). The *let-7/LIN-41* pathway regulates
- 7 reprogramming to human induced pluripotent stem cells by controlling expression of

8 prodifferentiation genes. Cell Stem Cell 14, 40-52.

9 Yokoyama, S., Hashimoto, M., Shimizu, H., Ueno-Kudoh, H., Uchibe, K., Kimura, I.

and Asahara, H. (2008). Dynamic gene expression of Lin-28 during embryonic
development in mouse and chicken. Gene Expr. Patterns *8*, 155-160.

- 12 Yoshida, K., Kawakami, K., Abe, G. and Tamura, K. (2020). Zebrafish can regenerate
- endoskeleton in larval pectoral fin but the regenerative ability declines. Dev. Biol. *463*,
  110-123.
- 15 Yu, J., Vodyanik, M.A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J.L., Tian, S.,
- 16 Nie, J., Jonsdottir, G.A., Ruotti, V., Stewart, R., *et al.* (2007). Induced pluripotent stem
- cell lines derived from human somatic cells. Science *318*, 1917-1920.
- 18 Zhang, H.M., Chen, H., Liu, W., Liu, H., Gong, J., Wang, H., and Guo, A.Y. (2012).
- AnimalTFDB: a comprehensive animal transcription factor database. Nucleic Acids
  Res. *40*, D144-D149.
- Zhou, Q., Brown, J., Kanarek, A., Rajagopal, J. and Melton, D.A. (2008). In vivo
  reprogramming of adult pancreatic exocrine cells to beta-cells. Nature *455*, 627-632.

75









## Fig. 4 Atsuta et al.



Fig. 5 Atsuta et al.



Ò

2

14

Days after infection and 3D culture Trajectory to fate 
Transit (A1/A2/T1/T2/T3) 
rLPC (r1/r2/r3/E9)

2

à

## Fig. 6 Atsuta et al.

14

Reprogramming



Fig. 7 Atsuta et al.